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ABSTRACT 
 
The Hippo pathway integrates numerous stimuli into intracellular signaling 
that informs the cell of its structural features (actin cytoskeleton, polarity, cell 
shape), location, and surroundings (cell-cell contacts, growth factors, extracellular 
matrix), instructing cellular survival, proliferation, differentiation and fate. 
Dysregulated Hippo signaling leads to cell fate and developmental defects, and 
promotes tumorigenesis. We investigated the role of Hippo pathway transcriptional 
regulators YAP and TAZ (YAP/TAZ) in cancer metabolic reprograming and 
showed that they regulate the expression of glutamine transaminases that promote 
glutamine dependence in breast cancer cells. In breast cancer patients, YAP/TAZ 
activity positively correlates with transaminase expression, identifying 
transamination as a prospective clinical target in breast cancers driven by aberrant 
YAP/TAZ function. Critical regulators of cancer progression in the tumor 
microenvironment (TME) are T cells, whose activation and differentiation relies on 
signals regulated by the Hippo pathway in other contexts. We studied the effect of 
T cell specific YAP deficiency in anti-tumor T cell mediated immunity, which led us 
in identifying YAP as a suppressor of T cell activation and function. YAP deficiency 
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enhanced CD4+ T cell differentiation to polarized subtypes. In in vivo mouse tumor 
models, YAP deficiency reduces tumor growth and augments the ability of CD8+ T 
cells to infiltrate tumors. Tumor infiltrating lymphocyte RNA-Seq identified YAP as 
a global suppressor of T cell responses in the TME and as a key negative regulator 
of T cell tumor infiltration and patient survival in many human cancers. Given these 
newly discovered effects of YAP in T cell biology, we further studied how YAP/TAZ 
deficiency affects the hallmark of adaptive immunity, T cell memory, during 
bacterial and viral infection and found that YAP/TAZ inhibit memory T cell 
generation. Lastly, we investigated the role of Hippo pathway kinases and 
YAP/TAZ inhibitors LATS1 and LATS2 in T cells and found that in contrast to 
YAP/TAZ they are indispensable for normal thymocyte development and function. 
Through this work, we define novel and critical roles of Hippo pathway signaling in 
T cell development and function, as well as cancer metabolic reprograming and 
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CHAPTER 1: INTRODUCTION 
 
1.1 Overview of the Hippo pathway and scope of thesis 
The Hippo pathway confers cells the ability to sense and respond to their 
microenvironment by integrating and converting cell shape, polarity, cytoskeleton, 
extracellular matrix, metabolic and growth factor cues into intracellular signaling 
that regulates major signaling pathways in the cytoplasm and gene expression in 
the nucleus [1]. In its classical view, the pathway is composed of a conserved 
kinase cascade that is initiated by the activation of kinases MST1 and MST2 
(MST1/2). MST1/2 phosphorylate and activate kinases LATS1 and LATS2 
(LATS1/2), which in turn phosphorylate transcriptional regulators YAP and TAZ 
(YAP/TAZ). This phosphorylation event leads to YAP/TAZ sequestration in the 
cytoplasm via 14-3-3 protein interactions and degradation, resulting in inhibition of 
YAP/TAZ nuclear accumulation and interaction with a variety of transcription 





Figure 1.1. The core mammalian Hippo pathway. Adapted from Hiemer et al, 
2013 [2]. 
 
Hippo pathway signaling controls many processes important for animal 
development and homeostasis, including cell death, survival and proliferation, 
stem cell maintenance, cell fate determination and differentiation, tissue patterning 
and regeneration, as well as epithelial-mesenchymal transition (EMT) and wound 
healing, while deregulation of the Hippo pathway has critical implications in cancer 
[2, 3]. Therefore, major research efforts are focused on delineating upstream 




pathway activators or repressors that could be used as targets for a variety of 
outcomes, including regenerative medicine and cancer treatment.  
More specifically, nuclear YAP/TAZ is necessary for stem cell and tissue 
specific progenitor cell maintenance in many organ systems and differentiation to 
specialized epithelial cells coincides with activation of the Hippo pathway and loss 
of YAP/YAZ [1, 2].  This highly orchestrated process depends on multiple signals: 
contact inhibition by cell adhesion, establishment of tissue architecture maintained 
by actin-myosin networks, and assembly of apicobasal polarity networks ensure 
suppression of proliferation and initiation of differentiation programs through 
inhibition of YAP/TAZ. YAP/TAZ are nuclear when the ECM is stiff, when there are 
increased actin stress fibers and when cell shape is spread out. Conversely, soft 
ECM, confinement of cells on a small surface, and stress fiber formation leads to 
Hippo pathway activation and loss of YAP/TAZ. Various extracellular factors 
impact YAP/TAZ activity, such Wnt and TGF growth factors that impact YAP/TAZ 
function through cytoplasmic and nuclear interactions, and phosphatidic acid (PA), 
lysophosphatidic acid (LPA), sphingosine-1-phosphate (S1P) and estrogen also 
activate YAP/TAZ through GPCR-induced signals [1, 4]. 
The implications of loss of contact inhibition and cell polarity, disruption of 
tissue architecture, increased matrix stiffening and aberrant WNT, TGF and 
GPCR signaling on the Hippo pathway can be appreciated in the context of cancer: 
these disruptive events lead to YAP/TAZ nuclear localization and tumor initiation 




capacities like stem cell properties, increased cell survival and resistance to growth 
suppression, sustained proliferation, ability to initiate EMT and metastasize, 
resistance to various approaches of cancer therapy and metabolic rewiring [4, 6, 
7].  
We were interested in investigating the role of YAP/TAZ in the context of 
cancer, particularly in cancer cell metabolism, which led to our finding that 
YAP/TAZ play a key role in the glutamine addiction of cancer cells.  However, it 
was also clear that gaps of knowledge existed for how the Hippo pathway 
contributes to cancer immunology. My studies therefore also focused on defining 
a role for YAP in anti-tumor T cell responses, and ultimately identifying YAP as an 
intrinsic inhibitor of T cell activation and function. Since YAP affects primary T cell 
responses, we reasoned that it might also affect memory T cell development, so 
we used bacterial and viral infection models to study how YAP/TAZ deficiency 
influences T cell T cell memory. Lastly, we investigated the role of Hippo pathway 
kinases LATS1 and LATS2 in T cell development and function.  
 
1.2 Cancer Metabolism 
Metabolic reprogramming is one of the hallmarks of cancer, as transformed 
cells need to adjust their cellular energetics to meet increased energy demands 
that support uncontrolled proliferation, extended survival and metastasis [8]. Many 
oncogenes are linked to metabolic regulation that lead to uncontrolled growth, 




biosynthesis. Cancer cells rely excessively on aerobic glycolysis, increasing as a 
result their glucose uptake but they also heavily rely on glutamine, the catabolism 
of which provides non-essential amino acids, feeds into the TCA cycle and helps 
with balancing redox, resulting in improved cancer cell survival and proliferation 
[9-11]. In fact, many cancer cell lines display what is termed glutamine addiction, 
as removal of glutamine from cell culture media leads to cell death, and targeting 
glutamine metabolism has been proposed as a potential therapeutic approach [12]. 
Increased glutamine uptake in cancer is achieved through upregulated 
expression of glutamine transporters on their surface, such as SLC1A5 [13]. 
Glutamine is an important source of nitrogen for biosynthetic pathways and its 
main metabolic fate is to supply nitrogen to produce aspartate, alanine and serine 
through the breakdown of glutamate to an amino nitrogen and α-ketoglutarate [12, 
14]. Aminotransferases glutamate-oxalate transaminase (GOT), glutamate-
pyruvate transaminase (GPT) and phosphoserine aminotransferase 1 (PSAT1) 
catalyze this process. Asparate, alanine and serine all contribute to cancer cell 
metabolism and protein synthesis downstream of glutamine [15]. Glutamine is also 
important in anaplerosis, the process by which TCA cycle metabolic intermediates 
that have been used up for biosynthesis are replenished. Cancer cells rely heavily 
on anaplerosis for their metabolic processes, and as a result on glutamine [15]. 
Lastly, glutamine can be converted to glutamate to contribute to the generation of 
glutathione (GSH), which is necessary for redox homeostasis and cancer cell 





Figure 1.2. Metabolic fates of glutamine.  
 
Therefore, elucidating mechanisms by which cancer cells augment their 
abilities to take up and metabolize glutamine and use its derivatives can lead to 
the identification of new strategies for cancer therapy. 
 
1.3 T cells, activation and function 
T cells are essential components of our immune system and belong to the 
adaptive branch, defined by antigen specific recognition, clonal expansion and 
formation of immunological memory [16]. The T cell response is not only specific, 
it is also diverse, as there is a vast repertoire of possible antigens. Antigen specific 
T cells that have never encountered antigen before, called naive T cells circulate 




somewhere in the range of 1 in 100,000 [17-19]. Once they encounter their 
cognate antigen, they become activated and clonally divide about 15-20 times, 
increasing their number 50,000 to 500,000-fold [17]. This is the expansion phase 
of the adaptive immune response, during which naïve T cells dramatically expand, 
differentiate into an army of effector T cells that migrates to the site of infection and 
clears pathogens by direct killing of infected cells and secretion of effector 
cytokines. The peak of this response is around 7 to 12 days post-infection, after 
which the vast majority of effector T cells die, while about 5% remains to form a 
long-lived memory T cell pool. Memory T cells have the ability to rapidly respond 
to antigen re-exposure by efficient expansion and effector function that forms the 





Figure 1.3. Primary and secondary T cell responses to infection or 
immunization. Adapted from Paul (2013) [20]. 
 
T cells are divided into two sub-lineages: those that express the CD4 co-
receptor are CD4+ T cells and those that express the CD8 co-receptor are CD8+ T 
cells [20]. These cells recognize antigen in different ways and they differ in their 
regulatory and effector functions. T cells mediate their antigen specific functions 
by means of the T cell receptor (TCR), which recognizes a peptide derived from 
intracellular proteolysis on an antigen presenting cell that is mounted on a class I 




T cells recognize peptide on MHC class I. Class II MHC is found on antigen 
presenting cells (APCs) such as B cells, dendritic cells and macrophages whereas 
class I MHC is found on most cells, and as a result CD4+ and CD8+ T cells are 
presented with antigen from different cell sources which affects their function [20].  
APCs endocytose pathogens or tumor cells, they cleave proteins 
proteolytically in the endosome and lysosome, and load peptides into MHC class 
II molecules expressed on their surface where they are bound by CD4+ T cells with 
the appropriate TCR that recognizes that specific peptide:MHC complex [20]. As a 
result, CD4+ T cells mainly interact with extracellularly derived peptides on MHC 
Class II on the surface of macrophages or dendritic cells. MHC class I molecules 
are mainly loaded with peptides derived from intracellularly synthesized proteins, 
such as viral ones, or mutated cancer antigens produced by proteolysis in the 
proteasome and rough endoplasmic reticulum translocation. Such peptide: MHC 
Class I complexes on the surface of all nucleated cells can be recognized by CD8+ 
T cells expressing the right TCR. Therefore, CD8+ T cells can recognize antigen 
on the surface of all infected or transformed cells. The most efficient CD8+ T cell 
priming (i.e. initiation of an immune response) however is done by dendritic cells 
that express both MHC Class I and II and can take up antigens produced by 
infected or dying tumor cells and activate CD8+ T cells through cross-presentation 
[20]. 
The engagement of the peptide:MHC complex with the TCR is not sufficient 




stimulatory signal derived from engagement of CD28 on the T cell with CD80 and 
CD86 on the APC leads to full T cell activation [21]. This interaction induces the 
expression and secretion of a critical T cell derived growth factor, cytokine IL2. 
Together, these three signals, namely, TCR interaction with peptide:MHC, CD28 
interaction with CD80 and CD86 and autocrine IL2 lead to T cell activation, 
expansion and differentiation. Upon T cell activation, a series of intracellular 
signaling cascades are initiated leading to transcriptional changes that determine 
cytokine production, survival, proliferation, differentiation and ultimately, T cell fate 
[20]. In addition to their direct capacity to target and kill infected cells, T cells are 
also able to improve the microbicidal function of other immune cell types, such as 
improving the ability of B cells to produce antibodies, increase the microbicidal 
capacity of macrophages, or inhibit immune responses [20]. Importantly, activated 
CD4+ T cells are integral for the activation and licensing of dendritic cells to induce 
CD8+ T cell priming [20].  
 Depending on their microenvironment, CD4+ T cells, otherwise known as 
helper T cells (TH) differentiate into a variety of different polarized phenotypes 
each with their own specialized function, defined by signature transcription factors 
and by their ability to secrete a different range of cytokines [22]. The best 
characterized of these subtypes are TH1, TH2, TH17 and Treg (Figure 1.4).  TH1 
cells are important for the elimination of intracellular pathogens through their own 
effector functions and through monocyte and macrophage recruitment, and in 




themselves, and their signature transcription factor is Tbet. For IL4 and IL5 
producing TH2 cells, the critical inducing cytokine is IL4 and the signature 
transcription factor is GATA3. Their function is necessary for antibody production 
by B cells, for the host response against extracellular parasites and they also 
induce asthma and allergies. TH17 cells function against extracellular bacteria and 
fungi, they recruit granulocytes and they are also involved in autoimmune disease. 
They are induced by IL6, IL21, IL23 and TGF, they are maintained by the activity 
of transcription factor RORt and they secrete IL17. Regulatory T cells (Tregs) are 
immunosuppressive and their function is important for self-tolerance and 
suppression of autoimmunity, as well as suppression of the immune response after 
infection. They are induced by IL2 and TGF and their signature transcription 
factor is Foxp3.  These cells produce IL10 and TGF. Therefore, all these different 
subsets are necessary in normal immune homeostasis and to protect against 
pathogens, but their aberrant differentiation can lead to autoimmunity, allergies, 
and contribute to cancer.  It is noteworthy that there is a high degree of plasticity 





Figure 1.4. CD4+ T cell fates. Adapted from Paul (2013) [20]. 
 
CD8+ T cells develop into cytotoxic T lymphocytes (CTLs), cells that 
possess the striking function of efficiently lysing target cells that express their 
cognate antigen on their MHC class I molecule [23]. They do so by employing 
several mechanisms, one of which is by inducing apoptosis through engagement 
of FAS ligand (FASL) on the T cell with FAS on the target cell. They also cause 
granule mediated cell death, whereby exocytosis of perforin, a protein able to form 
pores on the plasma membrane of the target cell is combined with release of 




Upon T cell activation through the TCR and co-stimulatory receptors, there 
is upregulation of co-inhibitory receptors that attenuate costimulatory signals 
leading to inhibition of T cell proliferation and function [24]. Cytotoxic T-
lymphocyte-associated protein 4 (CTLA4) and programmed cell death protein 1 
(PD1) are two very well characterized inhibitory receptors that become expressed 
after T cell activation. Such negative feedback loop is necessary to ensure that T 
cells become de-activated once they clear their target and inflammation is 
resolved, as prolonged activation can lead to pathogenic inflammation, immune 
mediated tissue damage, and auto-immunity. In chronic infection or cancer where 
antigen persists, elevated and sustained expression of these immune checkpoints 
otherwise necessary for homeostasis lead to T cell terminal differentiation to a non-
functional exhausted state [25]. With T cells in an exhausted state, infection is not 
resolved and in cancer, tumors are allowed to grow and metastasize.  
 
1.4 T cells in cancer 
The immune system can protect against tumor formation, but it can also 
drive tumor progression by altering the immunogenicity of the tumor [26-28]. The 
term “cancer immunoediting” was coined to refer to the process by which the 
immune system exerts these opposing effects in cancer [28]. The process of 
immunoediting consists of three phases: elimination, during which the immune 
system is successful in containing a tumor before it becomes clinically detectable; 




but at the same time the immune system is shaping immunogenicity in surviving 
tumor cells; and finally escape, in which the tumor cells have managed to escape 
the immune system leading to tumor growth and metastasis [28-30]. There are a 
number of mechanisms observed in tumor cells that lead to immune escape and 
eventually tumor outgrowth. Tumor cells can escape immune recognition by 
downregulating tumor antigens, or MHC molecules themselves, they resist the 
cytotoxic effects of T cells by upregulating survival genes, such as BCL2, they can 
secrete immunosuppressive cytokines and cytokines that enhance angiogenesis 
(VEGF, TGF, CSF1, CSF2, IL-6), express immunosuppressive receptors (CD73, 
CD39, PD-L1, galectins) as well as enzymes whose products lead to 
immunosuppression (arginase, TDO, IDO) [29]. They can escape the immune 
system by attracting MDSCs, M2 macrophages and DCs that also express 
immunoregulatory molecules such as arginase, iNOS and IDO and secrete 
immunosuppressive cytokines IL-10 and TGF-β that inhibit CD8+ T cell 
proliferation or induce apoptosis. The same leukocytes can also induce regulatory 
T cells that themselves express inhibitory receptors (PD-1, CTLA-4, Tim-3, LAG3) 
that suppress anti-tumor immune response and favor tumor outgrowth [29, 31]. 
Interestingly, tumors that have developed the latter immune escape 
mechanism are immune infiltrated and they can respond well to immunotherapy, 
whereas patients lacking a T cell infiltrate cannot benefit from it [32, 33]. 
Histopathological analysis of patient tumors has shown that there is a subset of 




tumors. T cell infiltration has been shown to have a protective effect, as there is an 
inverse correlation between growth of the primary tumor, metastatic spread and T-
cell infiltration, and can be used as a marker for a positive disease prognosis [34-
36]. Evidence suggests that using immunological biomarkers can have higher 
predictive accuracy than tumor staging (AJCC/UICC-TNM classification) [33]. For 
example, in non-relapsing patients, the extent of T cell infiltration and tumor stage 
are inversely correlated, however, in patients who relapse, T cell infiltration is low 
irrespective of the tumor stage, suggesting that although the tumor is at an early 
stage, patients with a low immune infiltrate will relapse [37]. It is now an ongoing 
effort to incorporate a patient’s Immunoscore to their AJCC/UICC TNM-
classification before making a prognosis [33]. In addition to serving as a biomarker 
for cancer classification, a patient’s Immunoscore can be used to predict response 
to therapy. Immune checkpoint inhibition therapy for cancer has been shown to 
successfully reverse T cell exhaustion and lead to tumor clearance, however not 
all patients are responsive to it. In fact, the patients who can benefit from using the 
anti–CTLA-4 monoclonal antibody ipilimumab and the anti-PD1 monoclonal 
antibody nivolumab are the ones whose tumors are immune infiltrated [38-40].  
In addition to immune checkpoint inhibition, the development of chimeric 
antigen receptor T cells (CAR-T) has shown great promise in the treatment of 
hematological cancers [41]. CAR-T cells are genetically engineered to recognize 
a dominant tumor antigen and express several co-stimulatory molecules to ensure 




challenges still remain, as CAR-T cells are also susceptible to exhaustion and 
tumors still develop ways to downregulate the targeted antigen [42]. In fact, the 
success of CAR-T cell therapy has so far been limited to  hematological cancers, 
as the highly immunosuppressive tumor microenvironment inhibits the ability of 
CAR-T cells to penetrate and kill solid tumors [42]. Therefore, identifying 
mechanisms and devising strategies to improve T cell infiltration into solid tumors 
is currently considered the holy grail for cancer immunotherapy [43]. 
 
1.5 T cell memory  
 Following antigen exposure and resolution of inflammation, either through 
infection or vaccination, the small pool of antigen specific naïve T cells generates 
a heterogeneous pool of memory T cells, each with its own functional and 
phenotypic properties that can confer long lasting immunity against that antigen. 
The long term survival and self-renewal of these subsets that include central 
memory (TCM), effector memory (TEM) and resident memory (TRM) T cells is 
dependent on IL7 and IL15 cytokine signaling [44]. TCM reside mostly in lymph 
nodes and they have great proliferation and secondary effector generation 
potential, whereas TEM and TRM are dispersed throughout the periphery in the 
blood and mucosal areas where they are more likely to be exposed to pathogens. 
While TEM and TRM have reduced clonal expansion capacities compared to TCM, 




 How this diverse pool of memory T cells is generated upon antigen 
exposure is under investigation, and several mechanisms have been proposed 
(Figure 1.5) [45]. One model argues that the fate of a naïve T cell is pre-
determined during development in the thymus, however this is unlikely, as a single 
naïve T cell can give rise to short lived effectors as well as TEM and TCM cells [46, 
47]. In another model, memory T cell potential decreases with increased exposure 
to antigen, creating a pool of effector T cells at varying differentiation states 
depending on the sum of signals they have received during the course of infection 
[48-51]. The signal strength model argues that the concentration of peptide–MHC 
complexes and co-stimulatory molecules on the APC engaged by the T cell, 
together with  the duration of the T cell-APC interaction determines T cell fate, 
with stronger signal leading to greater terminal differentiation and loss of 
memory potential [52]. Asymmetric cell division has also been proposed as a 
mechanism for generating varying T cell fates, such that one daughter cell will give 
rise to an effector T cell and another to a memory T cell based on asymmetric 






Figure 1.5. Models for memory T cell generation. A. Separate precursor model. 
B. Decreasing potential model. C. Signal strength model. D. Asymmetric cell fate 
model. Adapted from Paul (2013) [20]. 
 
 Metabolic, transcriptional and epigenetic changes also regulate naive T cell 
differentiation into effector and memory subsets and help define them [54, 55]. 
From a metabolism perspective, T cell activation and effector differentiation 
involves dramatic reprogramming of metabolic functions to meet increased 




cells rely on aerobic glycolysis and lipid biosynthesis. Exiting this highly 
proliferative state and entering a more quiescent memory state requires further 
metabolic reprogramming, characterized by fatty acid oxidation and oxidative 
phosphorylation. Interestingly, memory T cells differ from naïve T cells, even 
though they are both quiescent in that memory T cells can switch their metabolic 
programs more rapidly, owing to increased mitochondrial mass and spare 
respiratory capacity [57, 58]. Transcriptionally, several factors have been linked to 
short lived effector fate, such as Blimp1, ID2, STAT4 and T-bet, whereas other 
transcription factors induce and maintain a memory T cell phenotype, including 
Eomes, Bcl6, ID3, TCF1, STAT3 and Foxo1 [45, 55]. Through understanding the 
accessibility of genetic loci at various stages of T cell differentiation, recent studies 
reveal it is not only important to know a cell’s gene expression profile, but also 
which genes are available for rapid induction, as memory T cells need to maintain 
access to both naïve and effector associated genes for long term survival and rapid 
effector function, respectively [59-61]. 
 
1.6 T cell development  
T cells develop in the thymus during a highly orchestrated process the goal 
of which is to generate a diverse pool of self-tolerant T cells that can respond to a 
variety of foreign antigens [62, 63]. This process involves the migration of common 
lymphoid progenitors from the bone marrow to the cortico-medullary junction of the 




into mature T cells. During differentiation, thymocytes move from the cortex to the 
medulla, with each region providing distinct microenvironments for their maturation 
and eventually enter the periphery as naïve T cells [64]. Defects in T cell 
development in the thymus can result in serious pathologies, such as 
immunodeficiency, autoimmunity and cancer. 
The stages of T cell development in the thymus can be defined by tracing 
the cell surface expression of CD4, and CD8. Double negative thymocytes (DN) 
express neither CD4 nor CD8. They mature in the cortex of the thymus and the 
goal of their maturation process is to express a functional T cell receptor. (TCR). 
T cells need to recognize a vast number of foreign antigens and they do so through 
their TCR. TCRs are generated by DNA rearrangement in the thymus that gives 
rise to millions of different combinations. These TCRs are then tested in the thymus 
for their ability to engage with host MHC molecules, as this interaction is necessary 
for mounting an immune response. Once a TCR is formed, thymocytes begin to 
express CD4 and CD8 coreceptors on their surface and are presented with self-
antigens on MHC molecules on thymic cortical epithelial cells. Thymocytes that 
interact with MHC class I will differentiate into CD8 single positive cells (CD8SP), 
whereas thymocytes that interact with MHC class II will become CD4 single 
positive cells (CD4SP). Thymocytes that do not interact with self-antigen:MHC on 
the epithelial cells will die by apoptosis during the process of positive selection, 
which ensures that T cells will be able to interact with MHCs [65]. During TCR 




that recognize self-antigens. It is important that during thymic development those 
developing thymocytes are eliminated to establish immune tolerance. This is 
achieved by a process called negative selection: SP thymocytes migrate to the 
medulla where they are presented with self-antigens by medullary thymic epithelial 
cells and those that interact too strongly with self-antigens cells die by apoptosis. 






CHAPTER 2: GLUTAMINE-UTILIZING TRANSAMINASES ARE A 
METABOLIC VULNERABILITY OF TAZ/YAP-ACTIVATED CANCER CELLS  
(This section has been adapted from Yang, C.S., Stampouloglou, E., Kingston, 
N.M, Zhang, L., Monti, S., Varelas, X. Glutamine-utilizing transaminases are a 
metabolic vulnerability of TAZ/YAP-activated cancer cells. European Molecular 
Biology Organization Reports, 2018. 19(6) [66]. CSY and XV developed the 
concept and wrote the manuscript. CSY, ES, and NMK designed and performed 
experiments, with help from LZ and SM for bioinformatics analysis. CSY, ES, and 
NMK analyzed and visualized data. XV and SM supervised the project). 
 
2.1 Abstract 
The transcriptional regulators TAZ and YAP (TAZ/YAP) have emerged as 
pro-tumorigenic factors that drive many oncogenic traits, including induction of cell 
growth, resistance to cell death, and activation of processes that promote migration 
and invasion. Here, we report TAZ/YAP reprogram cellular energetics to promote 
the dependence of breast cancer cell growth on exogenous glutamine. Rescue 
experiments with glutamine-derived metabolites suggest an essential role for 
glutamate and α-ketoglutarate (AKG) in TAZ/YAP-driven cell growth in the 
absence of glutamine. Analysis of enzymes that mediate the conversion of 
glutamate to α-ketoglutarate (AKG) showed that TAZ/YAP induce glutamic-
oxaloacetic transaminase (GOT1) and phosphoserine aminotransferase (PSAT1) 




expression in breast cancer patients. Notably, we found that the transaminase 
inhibitor aminooxyacetate (AOA) represses cell growth in a TAZ/YAP dependent 
manner, identifying transamination as a potential vulnerable metabolic 
requirement for TAZ/YAP-driven breast cancer. 
 
2.2 Introduction 
Altered cellular energetics is an established hallmark of cancer [8], a 
premise supported by observations that oncogenes directly modulate metabolic 
circuits required for tumorigenesis [11, 67-69]. Oncogenic alterations in metabolic 
enzymes contribute to a variety of cancer-associated traits, including uncontrolled 
cell proliferation, alterations in cell polarity, increased metastatic ability, and 
evasion from cell death, indicating that aberrant cellular metabolism acts as a 
tumorigenic “driver” [11, 70-73]. Cancer-specific metabolic reprogramming 
therefore represents an exciting avenue for the development of novel diagnostic 
tools and targeted cancer therapy [15, 74]. 
The paralogous transcriptional regulators TAZ and YAP (herein referred to 
together as TAZ/YAP) have emerged as central factors in cancer biology. Nuclear 
TAZ/YAP activity has been shown to drive cell proliferation, survival, and mobility, 
and has key roles in directing cell fate [75]. Increased levels and activity of 
TAZ/YAP have also been shown to correspond with high grade tumors that 
generally lack effective therapeutics [3]. Advanced breast cancers in particular 




activity for driving breast cancer cell growth and aggressiveness [76, 77]. Thus, in 
depth understanding of the processes regulated by TAZ/YAP may provide 
important insight into the etiology of cancer and offer therapeutic opportunity.   
Here we report that TAZ/YAP promote glutamine dependence in breast 
cancer cells and activate the expression of glutamine-utilizing transaminases to 
support cell growth. We found that glutamine deprivation greatly reduces the 
growth of breast cancer cells with high TAZ/YAP levels, and that knockdown of 
TAZ/YAP mitigates cell death caused by glutamine depletion. Interestingly, we 
found that TAZ/YAP promotes the expression of the transaminases GOT1 and 
PSAT1, and blockade of transamination with aminooxyacetate (AOA) suppresses 
the growth of breast cancer cells in a TAZ/YAP-dependent manner. Collectively, 
our data indicate that glutamine addiction of breast cancer cells is mediated by 
TAZ/YAP and suggest that targeting of transamination could be exploited for 
breast cancer therapies to attenuate TAZ/YAP-driven tumor growth.  
 
2.3 Results 
TAZ/YAP control glutamine dependency of breast cancer cells. 
Given the emerging oncogenic roles of TAZ/YAP [3, 75], we thought to 
analyze the nutrient requirements associated with TAZ/YAP activation to uncover 
susceptible metabolic processes for potential targeting of cancer cells with hyper-
activated TAZ/YAP. To this end, we identified gene expression changes resulting 




(data from Enzo et al [78]), which is a cell line that exhibits high nuclear TAZ/YAP 
activity [79], and performed Gene Set Enrichment Analysis (GSEA) to determine 
whether any relationships exist with gene sets representing distinct metabolic 
features [72] (Dataset EV1, see citation [66]). Among 38 molecular signatures 
examined, 13 were downregulated upon TAZ/YAP deficiency (Table EV1, see 
citation [66]), suggesting a role for TAZ/YAP in stimulating these metabolic 
processes. Notably, the gene set representing amino acid metabolism showed the 
strongest statistical association with TAZ/YAP activity (Figure 2.1A and Table 





Figure 2.1. Breast cancer cell lines with elevated levels of TAZ/YAP cancer 
exhibit glutamine dependence. A. GSEA shows enrichment of amino acid 
metabolism-associated genes in gene expression signatures induced by 
TAZ/YAP. B. Lysates were isolated from density-matched mammary cells cultured 
in complete medium and examined for endogenous TAZ/YAP protein levels by 
immunoblotting. GAPDH levels were used to control loading. C. Cell growth of a 
panel of human breast cancer cell lines and a non-malignant human mammary 




medium and then normalized to growth in complete medium. The average relative 
percent growth of the in Q-free to complete medium is shown cells (n=3, mean +/- 
SD). The reduction in culture size following glutamine starvation is defined as 
glutamine-dependent growth (red), while the remaining growth following glutamine 
starvation is defined as glutamine-independent growth (blue). D, E. For the 
indicated cell lines, glutamine dependence measured in (C) was plotted against 
the expression levels of TAZ/YAP measured in (B) (shown in D), or the relative 
expression levels of the TAZ/YAP-targets CTGF/CYR61/ANKRD1/EDN1 
(determined from data available from the CCLE) (shown in E) to examine the 
correlation (A.U., arbitrary units) between these two biological features (see 
methods for details). 
 
Targeting amino acid metabolic enzymes in cancer cells has shown promise 
as a therapeutic strategy. In particular, enzymes important for metabolizing the 
“non-essential” amino acid glutamine have emerged as important mediators of 
cancer cell growth (i.e. proliferation and survival) [15, 74, 80-83], particularly in 
aggressive breast cancer cells [83]. We observed that several genes that encode 
important regulators of glutamine metabolism were reduced in expression 
following TAZ/YAP knockdown in MDA-MB-231 cells (Figure 2.2), which 
encouraged us to test the importance of glutamine in TAZ/YAP expressing cells  
To start, we tested whether TAZ/YAP levels correlate to glutamine dependence in 
a panel of human mammary cells, including 8 breast cancer cell lines and a non-
malignant human mammary epithelial cell (HMEC) line HMT-3522 S1 [84]. 
Immunoblotting for TAZ and YAP showed variable protein levels among these cells 
lines, ranging from very high levels in the more aggressive breast cancer cells 
(such as in MDA-MB-231 and HCC38) to very low levels in normal mammary 
epithelial cells (HMT-3522 S1) (Figure 2.1B). The removal of glutamine from 




(Figure 2.1C, red bars), whereas others grew robustly in the absence of 
exogenous glutamine (Figure 2.1C, blue bars). A strong positive correlation was 
observed between TAZ/YAP levels and glutamine dependence across these cells, 
with the growth of cells with pronounced levels of TAZ/YAP showing very strong 
glutamine dependence (Figure 2.1D). By examining gene expression data 
available from the Cancer Cell Line Encyclopedia (CCLE) project [85] we also 
observed a strong positive correlation between glutamine dependence and the 
expression of the YAP/TAZ target genes CTGF, CYR61, ANKRD1, and EDN1 
(Figure 2.1E). Taken together these observations suggested that TAZ/YAP 
activity may alter metabolic processes that drive exogenous glutamine reliance in 
breast cancer cells.  
 
Figure 2.2. The expression of several genes encoding regulators of 
glutamine metabolism is reduced following TAZ/YAP knockdown. The 
relative change in the expression of genes encoding glutamine regulators was 
examined in microarray data available from Enzo et al [78] in MDA-MB-231 cells 





Glutamine depletion has been shown to trigger cancer cell death [80, 81]. 
To further examine the dependence on glutamine in cells with different TAZ/YAP 
levels, we monitored the growth of two “high” TAZ/YAP cell lines (MDA-MB-231 
and HCC38) and two “low” TAZ/YAP cell lines (BT474 and HMT-3522 S1) in 
glutamine replete and depleted media. Cells were seeded at comparable numbers 
(Figure 2.3A, Day 0), and after a 4-day incubation in complete medium, cell 
confluency increased in all cells examined (Figure 2.3A, Day 0 vs Day 4 
+Glutamine (Q)). Removal of glutamine slightly reduced the confluence of low 
TAZ/YAP cells compared to that in complete medium (Figure 2.3A, left panel, Day 
4 ±Q). By contrast, only few cells with high levels of TAZ/YAP survived glutamine 
free conditions as evidenced by a significant drop of cell numbers (Figure 2.3A, 
right panel, Day 0 vs Day 4 -Q), suggesting that glutamine deprivation induces the 
death of cells with high levels of TAZ/YAP. We then performed cell counting and 
trypan blue exclusion assays to directly monitor the kinetics of cell death in MDA-
MB-231 and HCC38 cells transfected with control siRNA or siRNA targeting TAZ, 
YAP, or both TAZ and YAP together. The efficacies of the siRNAs were validated 
by immunoblotting for TAZ and YAP levels (Figure 2.4). In glutamine free medium, 
the numbers of both MDA-MB-231 and HCC38 cells that received control siRNA 
profoundly declined after being switched to glutamine free medium (Figure 2B, 
black lines), which was accompanied by an increase in cell death (Figure 2.3C, 
black bars). Interestingly, TAZ/YAP deficiency prevented the decline of the cell 




(Figure 2.3C, grey bars) caused by glutamine deprivation. TAZ depletion alone 
similarly protected the decline of the cell population (Figure 2.3B, blue lines) 
following glutamine deprivation, albeit at a lower level than depletion of both 
TAZ/YAP, whereas YAP depletion alone had minimal effects. This predominant 
reliance on TAZ for mediating glutamine dependence is consistent with a more 
dominant role for TAZ in mediating tumorigenic phenotypes and clinical outcomes 
in breast cancers [3].  
 
Figure 2.3. Downregulation of TAZ/YAP alleviates glutamine dependence of 
breast cancer cells. A. HMT-3522 S1 and BT474 (low TAZ/YAP), as well as MDA-
MB-231 and HCC38 (high TAZ/YAP) cells seeded at similar density were cultured 




taken before (Day 0) and four days after media change (Day 4). Scale bar = 100 
μm. B, C. Cells transfected with control siRNA (black line) or siRNA targeting either 
TAZ (blue line), YAP (green line), or both TAZ/YAP (red line) were cultured in 
glutamine free medium. (B) Cell numbers and (C) cell death were monitored at the 
indicated time points after medium switch. The average from three independent 
experiments is shown +SEM (*p<0.05; **p<0.01; ***p<0.001; unpaired two-tailed 
t-test). D, E. MDA-MB-231 cells were engineered to constitutively express mouse 
TAZ (mTAZ), which is insensitive to siRNA targeting human TAZ. Cells expressing 
mTAZ along with control cells were transfected with control siRNA or siRNA 
targeting TAZ/YAP, and then: (D) the levels of endogenous human TAZ, 
ectopically expressed mTAZ, and GAPDH (as a loading control) were examined 
by immunoblotting lysates from respective cell lines; or (E) were cultured in Q 
deprived conditions, and the relative growth of the cells was determined as a 
percentage of growth relative to complete media. The average from three 





Figure 2.4. Efficacy of TAZ and YAP siRNA. MDA‐MB‐231 or HCC38 cells 
were transfected with indicated siRNA. Lysates were analyzed by 
immunoblotting with a TAZ/YAP antibody (CST, #8418) to examine antibody 
specificity and TAZ and YAP knockdown efficiency.  
 
The more pronounced effects of TAZ depletion on cell growth following 
glutamine deprivation prompted us to next test the consequences of TAZ 




musculus TAZ (mTAZ) that is not targeted by the human siRNA we used for 
endogenous TAZ depletion (Figure 2.3D). We found that expression of mTAZ was 
sufficient to reverse the growth protective effects of TAZ/YAP depletion following 
glutamine withdrawal, leading to a marked decline in cell growth after being 
switched to glutamine free medium, similar to what was observed in control cells 
normally expressing high levels of TAZ/YAP (Figure 2.3E). Together these data 
implicate TAZ as an essential mediator of glutamine addiction of breast cancer 
cells, with YAP playing a redundant role. 
 
TAZ/YAP promote anaplerotic entry of glutamine through transamination. 
Glutamine serves as a precursor to provide carbon and nitrogen for the 
biosynthesis of metabolites that are involved in cancer survival and proliferation 
[15] (Figure 2.5A). To evaluate how different glutamine-metabolizing pathways 
mediate the growth of cancer cells with high TAZ/YAP levels, we tested the ability 
of several glutamine-derived metabolites to rescue the growth of MDA-MB-231 and 
HCC38 cells under glutamine deprived conditions. Supplement of 
dimethylglutamic acid, a cell permeable analog of glutamate, rescued the growth 
of both breast cancer cell lines in a dosage-dependent manner (Figure 2.5B, red 
bars), consistent with the role of glutamate being the predominant metabolic fate 
of glutamine in proliferating cells [15, 86]. Glutamate has been shown to promote 
cancer cell growth by maintaining the TCA cycle as an anaplerotic substrate, 




nonessential amino acids for protein synthesis [15] (Figure 2.5A). Notably, the 
addition of dimethyl 2-oxoglutarate, a membrane permeable analog that elevates 
mitochondrial -ketoglutarate (AKG) levels to promote the TCA cycle, greatly 
restored culture size in both cell lines following glutamine withdrawal (Figure 2.5B, 
blue bars). The addition of the glutathione precursor N-acetylcysteine (NAC) 
(Figure 2.5B, green bars) or non-essential amino acids (Figure 2.5C, purple bars) 
had limited effects. These results suggest that the TCA cycle is a main metabolic 






Figure 2.5. TAZ/YAP are required for glutamine-utilizing transaminase 
expression in breast cancer cells. A. A depiction of the metabolic fates of 
glutamine. B. MDA-MB-231 and HCC38 cells were cultured in glutamine starvation 
medium supplemented with indicated metabolites for 48 h. The addition of dimethyl 
glutamate and dimethyl 2-oxoglutarate (AKG) resumed cell growth in glutamine 
free medium in a dosage dependent manner, while the supplement of other 
glutamine-derived downstream metabolites showed no, or marginal, effects. The 
average from three independent experiments is shown +SEM (*p<0.05; **p<0.01; 




genes altered in expression by knockdown of TAZ/YAP (i.e. TAZ/YAP gene 
expression signature) were examined in gene expression data from 1088 breast 
cancer biopsy samples curated in TCGA BRCA dataset and 112 paired normal 
samples. The analysis of this data is shown as a heat map with each row 
representing a TAZ/YAP-regulated gene, and each column representing a sample 
that was ranked by TAZ/YAP activity score (purple bar on the top) calculated by 
the ASSIGN analysis [87]. Breast cancer samples (red) and normal samples 
(black) separated into two clusters, with the cancer samples aligning with higher 
TAZ/YAP activity. D. TAZ/YAP activity was positively correlated with the 
expression of several transaminases, and anti-correlated with the expression of 
both isoforms of glutamate dehydrogenase in 1200 mammary biopsy samples 
analyzed. The spearman’s correlation coefficient [R] between TAZ/YAP activity 
and indicated metabolic enzymes is shown by the length and color code of each 
bar. The corresponding p-values are shown next to each bar. E. MDA-MB-231 
cells were transfected with control siRNA (siCTL) or siRNAs targeting TAZ and 
YAP (siTAZ+siYAP), or a separate siRNA targeting both TAZ/YAP (siTAZ/YAP), 
and the protein levels of the transaminases GOT1 and PSAT1 and GAPDH (as a 
loading control) was assessed by immunoblotting. The changes in GOT1 and 
PSAT1 protein levels from three separate experiments was quantified relative to 
GAPDH and the average +SEM is shown (***p<0.001; unpaired two-tailed t-test). 
F.   RT-qPCR was performed to determine the relative expression of GOT1 and 
PSAT1 mRNA in MDA-MB-231 cells treated with control siRNA, siRNAs targeting 
TAZ and YAP, or a separate siRNA targeting both TAZ/YAP. The average 
expression levels from three independent experiments are shown +SEM (*p<0.05; 
***p<0.001; unpaired two-tailed t-test).  G. MDA-MB-231 cells were subjected to 
ChIP analysis using control rabbit IgG, TAZ, or TEAD4, antibodies. Samples were 
analyzed by RT-qPCR using primers recognizing an enhancer for the GOT1 gene, 
which is illustrated at the top of the panel. Normalized % input values are shown 
as the average of three independent experiments +SEM (*p<0.05; **p<0.01; 
unpaired two-tailed t-test).  H. Control cells and cells ectopically expressing mTAZ 
or MYC were transfected with control siRNA or siRNA targeting TAZ/YAP, and 
then the relative expression levels of GOT1, CTGF, MYC, YAP and human TAZ 
mRNA were assessed by RT-qPCR. Note the significant rescue of GOT1 and 
CTGF reduction resulting from TAZ/YAP depletion following the expression of 
mTAZ. The average from three independent experiments +SEM is shown 
(**p<0.01; unpaired two-tailed t-test). 
 
Glutamate can be converted to AKG through transamination or oxidative 
deamination. The former is mediated by transaminases, including the glutamic-




transaminases GPT1 and GPT2 (GPT1/2), and the phosphoserine 
aminotransferase PSAT1, while the latter is controlled by the glutamate 
dehydrogenases GLUD1 and GLUD2 (GLUD1/2). To gain more insights on how 
TAZ/YAP control this metabolic step in a pathophysiological setting, we analyzed 
gene expression profiles from 1088 breast cancer biopsies available from The 
Cancer Genome Atlas (TCGA) BRCA dataset [88], and compared them to 112 
paired normal samples for statistical associations between TAZ/YAP activity and 
the expression levels of aforementioned enzymes. To this end, we examined the 
expression pattern of a group of TAZ/YAP target genes as a proxy for TAZ/YAP 
activity, and performed Adaptive Signature Selection and InteGratioN (ASSIGN) 
analysis to calculate the TAZ/YAP activity score for each biopsy sample (See Shen 
et al [87] and Materials and Methods). When ranked by their TAZ/YAP activity 
score (Figure 2.5C, purple bars) most tumor samples (Figure 2.5C, red bars) were 
clustered together and showed a higher score than their surrounding benign 
tissues (Figure 2.5C, black bars), consistent with reported elevation of TAZ/YAP 
activity in breast cancer [76, 79]. Similar to what previous studies have suggested 
[76, 89, 90], basal and triple negative breast cancer samples exhibited higher 
TAZ/YAP activity than other subtypes (Fig 2.6). Interestingly, by examining the 
correlation of TAZ/YAP activity with genes encoding glutamine metabolism 
regulators, we found a strong positive correlation with GOT1 and PSAT1 




(Figure 2.5D), suggesting TAZ/YAP promotes transamination over oxidative 
deamination. 
 
Figure 2.6. TAZ/YAP activity in breast cancer subtypes. Patient samples 
curated in TCGA were classified into different subtypes by PAM50. ASSIGN 
analysis was performed (see Materials and Methods) to calculate TAZ/YAP activity 
score in each subtype. ANNOVA analysis showed a significant difference in 
TAZ/YAP activity scores between tumor subtypes (p < 2.2e-16 for both 
classification methods). The Mann-Whitney U test was performed to evaluate if 
Triple Negative breast cancer samples have a higher TAZ/YAP ASSIGN score 
compared with ER/Her2 samples, and if basal breast cancer samples have a 
higher TAZ/YAP ASSIGN score compared with other subtypes. In both cases, 
Triple negative and basal breast cancer samples show significantly higher 
TAZ/YAP activity (p < 2.2e-16). 
 
Given the established oncogenic roles of GOT1 and PSAT1 in breast 
cancer and their strong associations with TAZ/YAP activity in our ASSIGN 
analysis, we investigated whether TAZ/YAP control the levels these 
transaminases. For this, we examined GOT1 and PSAT1 mRNA levels by 
quantitative real-time PCR (qPCR) or protein levels by immunoblotting in cell 
lysates isolated from MDA-MB-231 cells transfected with control siRNA or two 




TAZ/YAP reduced both the protein (Figure 2.5E) and mRNA (Figure 2.5F) levels 
of GOT1 and PSAT1. To investigate whether TAZ/YAP directly mediate the control 
of GOT1 and PSAT1 gene expression we analyzed recent chromatin conformation 
capture (3C) and chromatin immunoprecipitation (ChIP)-sequencing data for 
YAP/TAZ from MDA-MB-231 cells [78] searching for binding to promoter or 
enhancer regions associated with these genes. We identified a potential binding 
site for YAP/TAZ and the TEAD transcription factors, which are binding partners 
of YAP/TAZ that are known to direct the pro-tumorigenic functions of YAP/TAZ 
[91], in a GOT1 enhancer (Figure 2.5G). Binding sites associated with the PSAT1 
gene were less clear. The potential association with a GOT1 enhancer prompted 
us to perform our own ChIP experiment using TAZ and TEAD antibodies, which 
revealed that indeed TAZ and the TEAD transcription factors are bound to the 
GOT1 enhancer (Figure 2.5G).  
Given the direct association of TAZ with the GOT1 gene, we next 
investigated whether TAZ expression was sufficient to induce GOT1 expression. 
For this, we used the MDA-MB-231 cells we generated that stably express mTAZ 
(Figure 2.7), which is not targeted by the siRNA that recognizes endogenous 
human TAZ. We found that expression of mTAZ was sufficient to increase the 
expression of GOT1 following the knockdown of human TAZ/YAP, which was 
similar to what we observed for the TAZ/YAP target CTGF (Figure 2.5H). GOT1 
expression is known to be affected by the levels of the transcription factor MYC 




association between MYC and TAZ/YAP activity in directing cell growth [94], we 
considered the possibility that changes in MYC levels contribute to the reduced 
levels of GOT1 following TAZ/YAP knockdown in MDA-MB-231 cells. To 
investigate the contribution of MYC to GOT1 expression, we generated MDA-MB-
231 cells stably expressing MYC (Figure 2.7). MYC expression was insufficient to 
rescue the reduced expression of GOT1 following TAZ/YAP knockdown (Figure 
2.5I), suggesting that TAZ/YAP directly induce the expression of GOT1. We did, 
however, observe changes in MYC mRNA and protein levels following TAZ/YAP 
knockdown, even for MYC expressed from a CMV promoter (Figure 2.5H), 
indicating that TAZ/YAP control MYC levels. Given the importance of MYC in 
controlling glutamine metabolism and dependence [93], it is thus likely that 
TAZ/YAP-mediated control of MYC levels contributes to the metabolic phenotypes 
observed in breast cancer cells with high TAZ/YAP levels.  
 
Figure 2.7. MDA‐MB‐231 cells expressing MYC or mTAZ. MDA‐MB‐231 cells 
were engineered to constitutively express mouse TAZ (mTAZ), which is insensitive 




were transfected with control siRNA or siRNA targeting TAZ/YAP, and the levels 
of endogenous human TAZ and ectopically expressed mTAZ, MYC, and GAPDH 
(as a loading control) were examined by immunoblotting lysates from respective 
cell lines.  
 
 
Inhibition of transamination preferentially suppresses breast cancer cells 
expressing high levels of TAZ/YAP. 
Given that glutamine-utilizing transaminases have been shown to support 
cell proliferation and stem cell renewal [82, 95],  we hypothesized that elevated 
levels of these enzymes might play key roles in cancer cells with high TAZ/YAP 
activity. To test this idea, we examined how the glutamate-dependent 
transaminase inhibitor aminooxyacetate (AOA) modulates the growth of cells 
expressing high (MDA-MB-231 and HCC38) or low levels of TAZ/YAP (BT474 and 
HMT-3522 S1). The growth of cells expressing “low” TAZ/YAP levels were 
refractory to the inhibition of transamination, indicating their growth was mostly 
independent of this metabolic reaction (Figure 2.8A). By contrast, the growth of 
two “high” TAZ/YAP cells was profoundly suppressed by AOA, resulting in more 
than 60% reduction in relative growth at highest dose tested (Figure 2.8A).  
Notably, the growth deficiency in the “high” TAZ/YAP MDA-MB-231 cells following 
AOA treatment was partially rescued by increased levels of exogenous AKG or 
Aspartate (Figure 2.9), consistent with a central role of the GOT transaminases in 






Figure 2.8. Blockade of transamination suppresses the growth of breast 
cancer cells in a TAZ/YAP dependent manner. A. The indicated “TAZ/YAP-low” 
and “TAZ/YAP-high” cells were treated with AOA (0, 0.25, 0.5, 1.0 mM) in complete 
medium. The culture size of AOA- and mock-treated cells was examined 48 h post 
treatment and the relative growth of AOA/mock was determined as a percentage. 
Notably, the breast cancer cells expressing elevated levels of TAZ/YAP were more 
sensitive to AOA (The average from three independent experiments +SEM is 
shown, with comparison to HMT-3522 S1, ###p<0.001; or BT474, *p<0.05; 
***p<0.001; unpaired two-tailed t-test). B. MDA-MB-231 (left) and HCC38 (right) 
cells transfected with control siRNA or siRNA targeting TAZ/YAP showed that 
growth suppression induced by AOA was significantly alleviated in cells depleted 




(*p<0.05; **p<0.01; unpaired two-tailed t-test). C. AOA induced MDA-MB-231 cell 
death was significantly alleviated following siRNA-mediated TAZ/YAP depletion 
compared to cells treated with control siRNA. The average from three independent 
experiments +SEM is shown (***p<0.001; unpaired two-tailed t-test). D. Control 
cells and cells ectopically expressing mTAZ were transfected with control siRNA 
or siRNA targeting TAZ/YAP, and the growth of cells was assessed in the presence 
or absence of 1mM AOA. The average relative growth +SEM of AOA/mock 
conditions from three independent experiments is shown (**p<0.01; unpaired two-
tailed t-test). E. MDA-MB-cells transfected with control siRNA or siRNA targeting 
TAZ/YAP were examined for the growth suppression effects induced by the 
glutaminase inhibitor BPTES. Notably, TAZ/YAP depletion significantly alleviated 
the relative growth of cells following BPTES treatment. The average from three 




Figure 2.9. AOA‐mediated repression of MDA‐MB‐231 cell growth was 
partially rescued by the addition of exogenous aspartate or dimethyl 2‐
oxoglutarate (AKG). The average from three independent experiments +SEM is 
shown (**p<0.01, ***p<0.001; unpaired two-tailed t-test). 
 
 
To elucidate whether TAZ/YAP control the sensitivity of cells to the inhibition 
of transamination, AOA sensitivity was examined in MDA-MB-231 and HCC38 
cells transfected with control siRNA or siRNA targeting TAZ and YAP. As shown 
in Figure 2.8B and Figure 2.8C, cells transfected with control siRNA remained 
sensitive to AOA, whereas depletion of TAZ/YAP significantly alleviated the growth 
suppression induced by AOA. We observed that AOA treatment induced cell death 




the AOA-induced cell death phenotype was partially rescued following TAZ/YAP 
knockdown (Figure 2.8C). We further observed that mTAZ expression, which is 
insensitive to knockdown by the human siRNA we used, was sufficient to 
overcome the protective effects of TAZ/YAP knockdown following AOA treatment 
in MDA-MB-231 cells (Figure 2.8D). Therefore, our data indicate a role for 
TAZ/YAP in mediating transaminase inhibitor sensitivity in breast cancer cells.  
Given the effects of transaminase inhibition on cells expressing high levels 
of TAZ/YAP, we decided to investigate whether inhibition of other enzymes 
important for glutamine metabolism might offer similar targeting potential. Inhibition 
of glutaminase activity has been shown to be effective in reducing tumorigenic 
phenotypes in various tumor models [96-98], and given the importance of 
glutamate in cells expressing high levels of TAZ/YAP, we speculated that inhibition 
of glutaminase activity might offer an additional vulnerability point in these cancer 
cells. Indeed, we observed that MDA-MB-231 cells exhibited growth sensitivity to 
the glutaminase inhibitor Bis-2-[5-phenylacetamido- 1,3,4-thiadiazol-2-yl]ethyl 
sulfide (BPTES), and that this growth suppression was reversed by depletion of 
TAZ/YAP (Figure 2.8E). Thus, these observations indicate that TAZ/YAP promote 
the sensitivity of cells to both transaminase and glutaminase inhibition in breast 






2.4 Conclusions and Future Directions 
Although the activation of the Hippo pathway effectors TAZ/YAP has been 
shown to accelerate cell proliferation in a variety of cancers, including breast 
cancers, little is known about how TAZ/YAP mobilize metabolism to support cell 
growth. Our analysis of TAZ/YAP-driven gene expression profiles revealed that 
amino acid metabolism signatures are repressed upon TAZ/YAP knockdown, 
suggesting that amino acid metabolism in breast cancer cells is stimulated by 
TAZ/YAP activity. This directed us to find a strong positive correlation between 
TAZ/YAP levels and the glutamine dependency of breast cancer cells. Knockdown 
of TAZ/YAP mitigated the decrease in cell numbers and the corresponding cell 
death in breast cancer cell lines with elevated levels of TAZ/YAP, demonstrating 
an essential role for TAZ/YAP in stimulating glutamine dependency. 
The addition of glutamate or AKG rescued the MDA-MB-231 and HCC38 
growth under glutamine deprived conditions, arguing an anaplerotic role of 
glutamine in maintaining the growth of breast cancer cells with elevated levels of 
TAZ/YAP. Among enzymes that mediate the conversion of glutamate into AKG, 
we found that the expression of genes encoding the transaminases GOT1 and 
PSAT1 are positively associated with TAZ/YAP activity in breast cancer patient 
biopsies curated by TCGA. Moreover, our examination of protein and RNA levels 
following TAZ/YAP knockdown indicated that TAZ/YAP-mediated induction of 
GOT1 and PSAT1 promotes alterations in glutamine metabolism that may 




that GOT1 is directly regulated by TAZ, which is likely recruited to GOT1 gene 
regulatory regions by the TEAD transcription factors.  Interestingly, the converse 
relationship was observed with glutamate dehydrogenase levels, with an anti-
correlative relationship with TAZ/YAP activity being observed in TCGA gene 
expression data, suggesting that TAZ/YAP direct a switch in the metabolic circuit 
that produces AKG. Our observations, as well recent observations by others [70, 
71, 99, 100], suggest an elaborate association between TAZ/YAP activity and 
enzymes directing glutamine metabolism. Of interest is the potential for TAZ/YAP-
mediated metabolic changes to impact stem cell fate. Glutamine metabolism has 
been shown to play a key role in maintaining stem cell properties, such as the 
pluripotency of embryonic stem cells [95, 101]. In particular, PSAT1 has been 
shown to mediate conversion of glutamine into AKG playing a key role in 
maintaining the mouse embryonic stem cell state [95]. Given the importance of  
TAZ/YAP in a variety of stem cell populations [1], including breast cancer stem 
cells [76], the link with glutamine metabolism in this context will be of interest to 
study. The connection between cell confluence, cell growth and glutamine 
metabolism are also relevant. Aspartate transaminase activity has been shown to 
be reduced in confluent mammary epithelial cell culture [102], contributing to cell 
quiescence under cell contact-mediated growth inhibition. Cell compaction under 
confluent conditions is well described to restrict nuclear TAZ/YAP localization and 
activity [103, 104], and signals that overcome compaction-mediated inhibition of 




compaction-mediated cytoskeletal changes that impact TAZ/YAP activity are 
central in coordinating glutamine metabolism. 
Notably, our studies with AOA show that breast cancer cells expressing 
higher levels of TAZ/YAP were sensitive to the blockade of transaminases, 
whereas cells with lower TAZ/YAP levels, including a non-malignant HMEC line 
and a breast cancer line, were fairly refractory. We similarly observed that MDA-
MB-231 cells, which have high levels of TAZ/YAP, are also sensitive to the 
glutaminase inhibitor BPTES. Further, the depletion of TAZ/YAP protected 
sensitive cell lines from AOA or BPTES-mediated growth suppression. These data 
therefore suggest that inhibitors of glutamine-utilizing enzymes can repress the 
growth of breast cancer cells with elevated TAZ/YAP activity, arguing that the 
assessment of TAZ/YAP activity in breast cancers may offer a means for predicting 
response to such therapies. 
 
2.5 Materials and Methods 
Cell culture 
The breast cancer cells used were purchased from ATCC. Human 
mammary epithelial cells (HMEC) HMT-3522 S1 and tumor-derived T4-2 cells 
were kindly provided by Dr. Mina Bissell (Lawrence Berkeley National Laboratory) 
and were cultured based on the protocol previously described [84, 105, 106]. Cells 
were grown at 37°C in the following media: HCC38, BT549, BT20, ZR-75-1, 




cultured in DMEM 5% FBS; HMT-3522 S1 were cultured in DMEM/F12 with 5% 
FBS, 250 ng/mL insulin, 10 μg/mL transferrin, 2.6 ng/mL sodium selenite, 0.1 nM 
estradiol, 1.4μM hydrocortisone, 5 μg/mL prolactin, 10 ng/mL EGF; HMT-3522 T4-
2 were cultured in DMEM/F12 with 5% FBS, 250 ng/mL Insulin, 10μg/mL 
transferrin, 2.6ng/mL sodium selenite, 0.1 nM estradiol, 1.4 μM hydrocortisone and 
5 μg/mL prolactin. MDA-MB-231 stable cell lines were generated by integrating the 
respective construct using lentiviral transduction followed by selection in 
puromycin (Invivogen). For stable MYC-expressing cells, the pCDH-puro-cMyc 
lentiviral vector directing expression of cMyc (#46970 [107], Addgene) was used, 
and for TAZ-expressing cells, the pLVXpuro system was used as we have 
previously described [79]. To measure glutamine dependence, cells were seeded 
at 1 x 105 per well in a 6-well plate and switched to replete or glutamine free media 
supplemented with 5% Gibco dialyzed FBS (ThermoFisher, 26400-044). For 
metabolite addition experiments, glutamine starvation medium was further 
supplemented as indicated with L-glutamic acid dimethyl ester hydrochloride 
(Sigma, 49560), L-serine methyl ester hydrochloride (Sigma, 412201), L-aspartic 
acid/aspartate (Fisher, BP374), dimethyl 2-oxoglutarate (Sigma, 349631) or N-
acetyl-L-cysteine (Sigma, A7250) at a final concentration of 2, 4, or 8 mM, or 
nonessential amino acid mixture (alanine, glycine, aspartate, asparagine, proline, 
serine) at a final concentration of 0.05, 0.1 or 0.2 mM, and then adjusted pH to 7.4 
and filtered. To inhibit transaminases, cells were treated with O-(Carboxymethyl) 




at indicated concentrations in complete medium for 48 hours. To inhibit 
glutaminase activity, cells were treated with BPTES (Sigma, # SML0601) for 48 
hours. For RNA interference, cells were transfected as previously described [73] 
with control siRNA (Qiagen, 1027310) or an equal molar mixture of siRNA targeting 
human TAZ (Thermo Scientific MQ-016083-00-0002) and/or YAP (Thermo 
Scientific MQ-012200-00-0002), or a single siRNA targeting both TAZ/YAP 
(UGUGGAUGAGAUGGAUACA). Knockdown efficiency was verified by 
immunoblotting.  
 
Cell viability and relative growth 
To quantify relative growth, cells were cultured as indicated for 48 h, and 
then fixed with 1% paraformaldehyde in PBS. Fixed cells were stained with 0.1% 
crystal violet (CV) in 10% EtOH for 10 minutes, and then properly washed under 
running water and air dried overnight. CV stain was extracted by gradually adding 
10% acetic acid, allowing the OD590 reading of each control group close to 
1.00.1. Absorbance values of the experimental groups were then normalized by 
the value of the corresponding control group and shown as percentages. Living 
and dead cell numbers were assessed by direct counting and trypan blue exclusion 






Cell lysates were collected and resolved by a 10% gel for SDS-PAGE as 
previously described [79]. Antibodies used included those recognizing GOT1 from 
Novus Biologicals (NBP154778), PSAT1 antibody (Abnova, H00029968-A01), 
TAZ/YAP antibody (Cell Signaling, 8418), MYC D84C12 antibody (Cell signaling, 
5605), and GAPDH antibody (Genescript, A00192-100). 
 
Bioinformatics and statistical analysis 
Gene Set Enrichment Analysis (GSEA) was performed as previously 
described [108], using published gene expression data from NCBI GEO 
(GSE59230) [78]. The metabolic gene sets utilized for GSEA were compiled from 
Possemato et al [72] and available in the Dataset EV1. The TAZ/YAP activity in 
patient biopsy samples was calculated by Adaptive Signature Selection and 
InteGratioN (ASSIGN) [87], based on the expression pattern of 588 TAZ/YAP 
targets that were defined as the TAZ/YAP signature. Those TAZ/YAP signature 
genes were selected from the aforementioned expression data [78] through a 
differential analysis of the samples transfected with control or two different 
TAZ/YAP shRNA. Corrected multiple hypothesis testing by the FDR Benjamini-
Hochberg (BH) method [109] was performed for identifying differentially expressed 
genes that change at least two folds and the FDR cutoff was set at 0.05. A list of 




Data from cell-based and qPCR experiments were shown as mean ± SEM 
and analyzed by unpaired two-tailed Student's t-test. The differences of the 
ASSIGN scores for different subtypes of breast cancer were analyzed by ANOVA 
followed by The Mann-Whitney U test as indicated in the figure legends. Spearman 
correlation analysis was performed to assess the correlation between the 
TAZ/YAP activity score derived from ASSIGN and the expression levels of 
indicated metabolic enzymes. 
To assess the combined expression of the TAZ/YAP targets CTGF, CYR61, 
ANKRD1 and EDN1, we performed a z-score transformation for the 4 genes (the 
expression of each gene was normalized by subtracting the mean expression and 
dividing by the standard deviation) and the summed z-score across the four targets 
for each cell line was then used for correlation calculation. 
 
Chromatin Immunoprecipitation (ChIP) 
MDA-MB-231 cells were used for ChIP experiments, using methods we 
have previously described [79]. The antibodies used included a rabbit TAZ 
antibody (Cell Signaling Technologies, 4883), and a rabbit TEAD4 antibody (Aviva, 
ARP38276-P050. Note that this antibody also recognizes TEAD1 and -3 [110]), 
and a control Rabbit IgG (Cell Signaling Technologies, 2729). Samples were 
analyzed by RT-qPCR to determine the percent input using the following primers 
that amplify a 127 bp region within a region in Chromosome 10 (Chr10: 




that functions an enhancer for GOT1 gene regulation [111]: 
GTTTTCCAACTGCTCCCTGC; AAGGAGCTTCCCTACCCCAT.  
 
Quantitative real-time PCR (qPCR) 
Extraction of total RNA and the synthesis of cDNA was performed as 
previously described [79]. Quantitative PCR was performed using Fast SYBR 
green mix (Applied Biosystems, 4385610) and measured on ViiA 7 real-time PCR 
system. Expression levels of each gene were calculated using the ΔΔCt method 
and normalized to cyclophilin. Sequences of primers are TAZ 
(CCATCACTAATAATAGCTCAGATC; GTGATTACAGCCAGGTTAGAAAG), YAP 
(CTCGAACCCCAGATGACTTC; CCAGGAATGGCTTCAAGGTA), GOT1 
(CAACTGGGATTGACCCAACT; GGAACAGAAACCGGTGCTT), PSAT1 
(ATTGTCCGTGATGACCTGCT; CGGCACCTCCATTGTTTTTA), MYC 
(AAGACAGCGGCAGCCCGAAC; TGGGCGAGCTGCTGTCGTTG), CTGF 







CHAPTER 3: YAP SUPPRESSES T CELL FUNCTION AND INFILTRATION IN 
THE TUMOR MICROENVIRONMENT 
(This section has been adapted from Stampouloglou, E., Frederico, A., Slaby, E., 
Monti, Stefano, Szeto, G.L. and Varelas, X. Yap suppresses T cell function and 
infiltration in the tumor microenvironment. bioRxiv, 2019: p. 644757 [112].  
ES, GLS and XV developed the concept and wrote the manuscript. ES designed 
and performed experiments, with help from E. Slaby and Nan Cheng. AF and SM 
performed the bioinformatics analysis. ES, E. Slaby and Nan Cheng analyzed and 
visualized data. XV and GLS supervised the project). 
 
3.1 Abstract 
A major challenge for cancer immunotherapy is sustaining T cell activation 
and recruitment in immunosuppressive solid tumors. Here we report that the levels 
of the Hippo pathway effector Yap are sharply induced upon the activation of CD4+ 
and CD8+ T cells and that Yap functions as an immunosuppressive factor and 
inhibitor of effector differentiation. Loss of Yap in T cells results in enhanced T cell 
activation, differentiation and function, which translates in vivo to an improved 
ability for T cells to infiltrate and repress tumors. Gene expression analyses of 
tumor-infiltrating T cells following Yap deletion implicates Yap as a mediator of 
global T cell responses in the tumor microenvironment and as a negative regulator 




Collectively, our results indicate that Yap plays critical roles in T cell biology, and 
suggest that Yap inhibition improves T cell responses in cancer. 
 
3.2 Introduction 
CD8+ and CD4+ T cells are central players in the adaptive immune system. 
T cells elicit targeted, antigen-specific responses for direct killing of an infected or 
transformed cell, shaping and regulating the immune response in host defense 
[16]. Most mature T cells circulate in a resting, naïve state, and upon cognate 
antigen recognition, T cells become activated, proliferate clonally, and differentiate 
into effector T cells. Naïve CD8+ T cells differentiate into cytotoxic T cells, while 
CD4+ T cells differentiate into an array of different types of helper (i.e., Th1, Th2, 
Th17) or regulatory T cells (Treg) depending on microenvironmental cues [113]. 
Each phenotype is defined by expression of signature transcription factors and 
effector cytokines leading to distinct functions [22]. 
T cell activation also upregulates negative feedback mechanisms, such as 
inhibitory receptors, which restrain their action to minimize pathogenic 
inflammation and autoimmunity [16, 114]. This network of immunosuppressive 
factors is frequently co-opted in chronic infections and cancer, leading to terminally 
differentiated and exhausted T cells that lose effector function and ability to 
infiltrate disease sites [115]. The finding that revitalization of exhausted, 
dysfunctional T cells can restore the immune response has revolutionized cancer 




cells (CAR-T), engineered for enhanced antigen recognition and co-stimulation 
also demonstrate promising clinical efficacy [117-119]. However, both 
immunotherapies are effective for only a fraction of patients [120-124]. Major 
challenges to extending the efficacy of immunotherapy to more cancer patients 
include sustaining T cell activation and achieving T cell infiltration in the 
immunosuppressive microenvironment of solid tumors [32-35, 37, 38, 125-128]. 
Improved understanding of mechanisms controlling T cell differentiation and 
function is critical to overcoming these barriers.  
Yap is a key effector of the Hippo signaling pathway, directing 
transcriptional programs that control stem cell biology by integrating 
microenvironmental and cell intrinsic cues [1]. Yap regulation leads to control of 
cell death and survival, proliferation and cell fate determination, and dysregulated 
Yap activity contributes to disease, most notably cancer [129]. While the dynamics 
of Yap regulation coupled with differentiation are well characterized in stem cells 
and tissue specific progenitor cells, less is known about the role of Yap in T cells. 
The Hippo pathway has been implicated in coupling CD8+ T cell clonal expansion 
to terminal differentiation through upregulation of kinase LATS1 and Yap 
degradation [130]. The Hippo pathway kinases MST1/2 have also been implicated 
in thymocyte egress and antigen recognition, lymphocyte polarization, adhesion 
and trafficking, survival, differentiation and proliferation [131-139]. Further, an 
immune-cell intrinsic role for Yap in CD4+ T cells has also been described, with 




Here, we investigated the role of Yap in primary CD4+ and CD8+ T cell responses 
like activation, proliferation and differentiation into effector T cell subsets and how 
Yap might affect T cell responses in cancer.  
We observed that Yap levels are elevated upon T cell activation, and that 
conditional deletion of the Yap gene in CD4+ and CD8+ T cells enhanced their 
activation and differentiation potential. These phenotypes translated in vivo to 
reduced growth of B16F10 melanoma and LLC lung cancer tumors in mice with 
Yap-deleted T cells. Importantly, T cell infiltration was substantially higher in these 
tumors. Using adoptive T cell transfer experiments, we observed that Yap-deleted 
polyclonal CD8+ T cells have an intrinsic ability to infiltrate tumors with much higher 
efficiency. RNA-sequencing analyses of Yap-deleted tumor infiltrating 
lymphocytes (TILs) revealed upregulation of key signaling pathways in T cell 
activation, differentiation and function in CD4+ and CD8+ T cells. Notably, we found 
that Yap-regulated gene expression changes were tumor-specific, as we observed 
minimal gene expression changes in lymphocytes isolated from tumor-draining 
lymph nodes (TDLNs). Yap-regulated gene expression signatures from TILs 
correlated with T cell infiltration and patient survival across multiple human cancers 
in The Cancer Genome Atlas (TCGA), including melanoma and lung cancer, as 
demonstrated in our mouse studies. Our study highlights Yap as a broad 
suppressor of CD4+ and CD8+ T cell activation and function, and a key regulator 





Yap inhibits CD4+ and CD8+ T cell activation. 
 To study the role of Yap in T cells, we started by analyzing Yap levels in 
isolated mouse primary CD4+ and CD8+ T cells that were either unstimulated or 
activated with anti-CD3/CD28 coated beads across a range of time points up to 24 
hours. We observed rapid induction of Yap protein in both CD4+ and CD8+ T cells 
upon in vitro activation (Figure 3.1A-B). This observation contrasted prior reports 
that Yap is exclusively expressed in Tregs or CD8+ T cells cultured under specific 
conditions [130, 140], which prompted us to explore roles for Yap in T cell 
activation and function. To gain insight into the roles of Yap in T cells, we generated 
a mouse model where Yap deletion and EYFP expression are induced under the 
control of the CD4 promoter (Yap-loxP/loxP: LSL-EYFP; CD4-Cre, herein referred 
to as Yap-cKO). Yap expression was efficiently reduced in both CD4+ and CD8+ T 
cells in Yap-cKO mice, which was expected given the activity of this Cre model at 
the CD4+CD8+ double-positive stage of T cell development (Figure 3.2A-B) and 
cells were also efficiently marked by EYFP expression (Figure 3.2C-D). No 
systemic defects or gross phenotypes were observed in Yap-cKO mice housed in 





Figure 3.1. Yap expression is induced upon T cell activation resulting in 
suppression of T cell activation. Wild type (WT) and Yap-cKO CD4+ and CD8+ 
T cells were isolated from mouse spleens and stimulated with CD3 and CD28 
coated magnetic beads to test expression of Yap protein and TEAD1-4 expression. 
T cell activation was tested using increasing concentrations of plate-bound αCD3 
with soluble αCD28 in Yap-cKO and WT T cells. Activation marker expression was 
also tested in WT CD4+ and CD8+ T cells treated with increasing concentrations of 
Verteporfin under IL-2, CD3 and CD28 stimulation. Statistical differences were 
determined by using an F test to identify differences between non-linear curve fits 
(C-F), (G-H), or one-way repeated-measures ANOVA with post-hoc test for linear 
trend with increasing verteporfin (I-J). A. Yap mRNA expression by CD4+ T cells 
isolated from WT or Yap-cKO mice 24 hours post CD3/CD28 stimulation 
(n=3/group). B. Yap mRNA expression by CD8+ T cells isolated from WT or Yap-
cKO mice 24 hours post CD3/CD28 stimulation (n=3/group). C. CD44 expression 
on WT and Yap-cKO CD4+ T cells 72 hours post CD3/CD28 stimulation (n=2-3 per 
dose/group). D. CD44 expression on WT and Yap-cKO CD8+ T cells 72 hours post 




Yap-cKO CD4+ T cells 72 hours post CD3/CD28 stimulation (n=2-3 per 
dose/group). F. CD25 expression on WT and Yap-cKO CD8+ T cells 72 hours post 
CD3/CD28 stimulation (n=2-3 per dose/group). G. TEAD1-4 expression in CD4+ T 
cells 24 hours post CD3/CD28 stimulation (n=3/group). H. TEAD1-4 expression in 
CD8+ T cells 24 hours post CD3/CD28 stimulation (n=3/group). I. CD71 expression 
on WT CD4+ T cells 72 hours post IL-2 and CD3/CD28 stimulation and increasing 
concentration of verteporfin (n=4/group). J. CD71 expression on WT CD8+ T cells 







Figure 3.2. Yap deletion or inhibition does not affect T cell proliferation. Wild 
type (WT) and Yap-cKO CD4+ and CD8+ T cells were isolated from mouse spleens 
and stimulated with CD3 and CD28 coated magnetic beads to test expression 
of Yap mRNA. T cell activation was tested using increasing concentrations of plate-
bound αCD3 with soluble αCD28 in Yap-cKO and WT T cells. Activation marker 




concentrations of Verteporfin under IL-2, CD3 and CD28 stimulation. Statistical 
differences were determined by using an F test to identify differences between 
non-linear curve fits (E-F), or one-way repeated-measures ANOVA with post-hoc 
test for linear trend with increasing verteporfin (I-K). A. Yap mRNA expression by 
WT or Yap-cKO CD4+ T cells 24 hours post CD3/CD28 stimulation. B. Yap mRNA 
expression by WT or Yap-cKO CD8+ T cells 24 hours post CD3/CD28 stimulation. 
C. EYFP expression by flow cytometry on CD4+ cells isolated from WT or Yap-
cKO mouse spleens. D. EYFP expression by flow cytometry on CD8+ cells isolated 
from WT or Yap-cKO mouse spleens. E. CD69 expression on WT and Yap-cKO 
CD4+ T cells 72 hours post CD3/CD28 stimulation. F. CD69 expression on WT and 
Yap-cKO CD8+ T cells 72 hours post CD3/CD28 stimulation. G. WT vs Yap-cKO 
CD4+ T cell proliferation (n=3/group). H. WT vs Yap-cKO CD8+ T cell proliferation 
(n=3/group). I. CD69 expression on WT CD4+ T cells 72 hours post IL-2 and 
CD3/CD28 stimulation and increasing concentration of verteporfin (n=4/group). J. 
CD69 expression on WT CD8+ T cells 72 hours post IL-2 and CD3/CD28 
stimulation and increasing concentration of verteporfin (n=4/group). K. 
Proliferation of DMSO vs verteporfin treated WT CD4+ and CD8+ T cells 
(representative of 4 independent experiments). 
 
 We next measured the surface levels of activation markers CD44, CD69, 
and CD25 in Yap-cKO T cells [141-144]. CD4+ and CD8+ T cells were isolated from 
wild type (WT) and Yap-cKO mouse spleens, activated by increasing 
concentrations of plate-bound anti-CD3, and levels of activation markers were 
measured 72 hours later. We found Yap-cKO CD4+ and CD8+ T cells were more 
sensitive to anti-CD3 dose compared to WT cells, showing increased expression 
of CD44 (Figure 3.1C-D), CD25 (Figure 3.1E-F), and CD69 (Figure 3.2E-F). 
CD44 and CD25 in CD4+ and CD8+ T cells exhibited significantly higher expression 
under all stimulation conditions tested, but CD69 expression only showed 
significance at intermediate anti-CD3 concentrations (0.25 and 0.5 μg/mL for CD8+ 
T cells, and 0.125 μg/mL for CD4+ T cells). CD4+ and CD8+ T cell proliferation was 




Yap-cKO cells 72 hours post-stimulation (Figure 3.2G-H). These data indicated 
that Yap plays an inhibitory role in T cell activation and that loss of Yap enhances 
the sensitivity of CD4+ and CD8+ T cells to T cell receptor signaling.  
 Yap functions as a transcriptional regulator, with most characterized roles 
describing the ability of Yap to regulate the TEAD family of transcription factors. 
Interestingly, we observed a substantial increase in the expression of TEAD1 and 
TEAD3 in CD4+ T cells, and TEAD1 in CD8+ T cells upon activation (Figure 3.1G-
H). These increases in TEAD expression prompted us to test the effects of the 
small molecule drug verteporfin (also known as Visudyne), reported to inhibit Yap-
mediated activation of TEADs, in T cell activation and proliferation [145]. 
Verteporfin treatment of CD4+ and CD8+ T cells isolated from WT mice increased 
levels of early activation markers CD69 (Figure 3.2I-J) and CD71 (Figure 3.1I-J) 
in a concentration-dependent manner. Similar to our observations with Yap-cKO 
cells, verteporfin treatment did not significantly affect proliferation of T cells isolated 
from WT mice 3 days post stimulation (Figure 3.2K). These data suggested that 
Yap-regulated transcription plays a suppressive function following T cell activation. 
 
Yap inhibits CD4+ T cell differentiation. 
Upon encountering their cognate antigen and receiving appropriate co-
stimulation, naïve CD4+ T cells become activated and can differentiate into several 
functionally diverse subsets, including Th1, Th2, Th17, and Treg. These subsets 




microenvironmental signals [22]. Signature transcription factors and effector 
cytokines define each subset: Th1 is defined by expression of T-BET and IFN, 
Th2 by GATA3 and IL-4, Th17 by RORt and IL-17, and regulatory T cells (Tregs) 
by Foxp3. Given the wealth of evidence for Yap playing key roles in stem cell 
regulation and differentiation, we hypothesized that deletion of Yap alters the 
differentiation potential of CD4+ T cells. To test this hypothesis, we isolated naïve 
CD4+ T cells from WT and Yap-cKO mice and cultured them under Th1, Th17, 
Th2, and Treg polarizing conditions [146, 147]. We found that Yap-deleted CD4+ 
T cells showed significantly enhanced Th1 (Figure 3.3A), Th17 (Figure 3.3B), Th2 
(Figure 3.3C), and Treg (Figure 3.3D) differentiation compared to WT cells, 
demonstrated by increased intracellular IFN, IL-17, GATA3, and Foxp3 
expression, respectively. We observed higher Foxp3 induction at lower 
concentrations of TGFβ in Yap-cKO cells compared to WT controls, indicating that 
Yap-deleted cells were more responsive to Treg differentiation conditions. 
Collectively, these observations were distinct from prior findings that suggested 
that Yap inhibits Treg differentiation and functions only in Tregs [140], and 
implicate Yap as an inhibitor of CD4+ T cell activation and differentiation into Th1, 





Figure 3.3. Deletion of Yap in CD4+ T cells results in increased IFN, IL-17, 
GATA3 and Foxp3 expression under Th1, Th17, Th2, and Treg polarizing 




isolated using magnetic beads. WT and Yap-cKO T cells were cultured under Th1, 
Th17, Th2, or Treg skewing conditions for 5 days in the presence of CD3 and CD28 
antibodies. On Day5, IFN, IL-17, GATA3, and Foxp3 expression were measured 
using flow cytometry. Statistical differences were determined by using a Student’s 
t-test (A-C) or an F test to identify differences between non-linear curve fits (D). A. 
IFN and IL-17 expression in WT and Yap-cKO CD4+ T cells under Th1 polarizing 
conditions (n=3/group). B. IFN and IL-17 expression in WT and Yap-cKO CD4+ T 
cells under Th17 polarizing conditions (n=3/group). C. IFN and GATA3 expression 
in WT and Yap-cKO CD4+ T cells under Th2 polarizing conditions (n=3/group). D. 
Foxp3 expression in WT and Yap-cKO CD4+ T cells under Treg polarizing 
conditions (n=3-6 per dose/group). 
 
Yap deletion does not alter T cell development or output in the thymus. 
Next, we compared thymic populations from WT and Yap-cKO mice to 
determine whether alterations in T cell development may play a role in the 
observed functional changes. During maturation in the thymus, precursor 
CD4+CD8+ double positive (DP) thymocytes go through positive selection to 
identify thymocytes expressing T cell receptors (TCR) that can functionally bind 
peptide-MHC complexes in the cortex [62]. Positively selected thymocytes become 
single positive (CD4SP or CD8SP), and migrate from the cortex to the medulla 
where self-reactive T cells die during negative selection, while surviving T cells exit 
into systemic circulation. Total cell counts were determined across the continuum 
of thymocyte maturation, including double negative (DN: CD4-CD8-), double 
positive (DP: CD4+CD8+), and single positive (SP: CD4+ or CD8+) stages (Figure 
3.4A). No significant changes were observed in total cell count at any stage, 
suggesting that output from positive and negative selection processes were not 





Figure 3.4. Thymocyte development is similar between WT and Yap-cKO T 
cells. Total thymocytes were isolated from thymuses of WT and Yap-cKO mice. 
Cells were stained and analyzed by flow cytometry for coreceptor maturation (A), 
positive selection (B), medullary maturation (C-E), and negative selection (F). 
Statistical differences were determined using two-way ANOVA followed by Sidak’s 
pairwise multiple comparisons tests. A. Absolute numbers of thymocytes in 
different maturation stages: double negative (DN), double positive (DP), single 
positive (SP) for CD4 and CD8 coreceptor expression (n=6-7 mice per group). B. 
Frequency of thymocytes progressing through positive selection determined by 
TCRβ and CD69 expression (n=6-7 mice per group). C. Frequency of 
TCRβ+CCR7+ SP thymocytes in semi-mature (SM) stage (CD69+MHCI-) (n=6-7 
mice per group). D. Frequency of TCRβ+CCR7+ SP thymocytes in mature 1 (M1) 
stage (CD69+ MHCI+) (n=6-7 mice per group). E. Frequency of TCRβ+CCR7+ SP 




Frequency of Nur77+ cells among DP, CD4SP, or CD8SP thymocytes (n=6-7 mice 
per group). 
 
Next, we analyzed the developmental progression of thymocytes through 
positive selection in greater detail using markers TCRβ and CD69. Yap-cKO mice 
compared to WT mice had no significant changes in the percentage of pre-
selection (TCRβ-CD69-), post-TCR engagement (TCRβ-CD69+), or mature 
(TCRβ+CD69-) thymocytes (Figure 3.4B). There were significantly more Yap-cKO 
thymocytes in the post-positive selection stage (TCRβ+CD69+) when compared to 
WT mice (approximately 1% increase in total cells). However, thymocyte frequency 
in the next maturation stage (TCRβ+CD69-) was similar between Yap-cKO and WT 
mice, indicating no significant change in output of mature TCRβ+CD69- cells. 
Overall, these observations suggest comparable selection output and TCRβ 
selection between Yap-cKO and WT mice.  
Positively selected SP thymocytes (TCRβ+CCR7+) can be further 
functionally defined using markers CD69 and MHC class I (MHCI; H-2kb) [148]. 
We observed no significant differences between Yap-cKO and WT mouse 
thymocyte frequency in CD69+MHCI- semi-mature (SM) (Figure 3.4C), 
CD69+MHCI+ mature 1 (M1) (Figure 3.4D), and CD69-MHCI+ mature 2 (M2) 
(Figure 3.4E) stages. CD69 and Nur77 are both markers of recent TCR 
engagement, and rapidly degrade after signal removal [149, 150]. However, CD69 
also controls thymocyte emigration and exit from the medulla, while Nur77 is more 




cell survival during negative selection to eliminate any T cells with high affinity self-
peptide-MHC binding and can induce apoptosis in immature thymocytes [154, 
155]. We therefore compared Nur77 levels in Yap-cKO with WT in DP and SP 
thymocytes to assess negative selection. Our analysis showed no increase in 
Nur77 expression in Yap-cKO mice compared to WT (Figure 3.4F), suggesting 
that Yap-cKO thymocytes do not receive prolonged TCR signaling relative to WT 
cells. Altogether, our data from thymic populations underscore that Yap deletion 
does not significantly change the number or percentage of cells during thymocyte 
development or thymic output. 
 
Deletion of Yap in T cells promotes T cell infiltration into solid tumors and 
blocks tumor growth. 
Having observed that Yap inhibits T cell activation and differentiation in vitro 
we decided to test the effect of Yap deletion in T cells following an immune 
challenge in vivo. For this, we decided to test anti-tumor T cell responses  using 
theB16F10mouse tumor model, due to its poorly immunogenic phenotype and 
highly immunosuppressive microenvironment that leads to low T cell infiltration 
[156-159]. Yap deletion in T cells resulted in superior anti-tumor immunity, as 
evidenced by the significant delay in tumor growth in Yap-cKO compared to WT 
mice (Figure 3.5A-B), consistent with prior observations [140].  We observed 




Yap-cKO mice (Figure 3.5C-D), suggesting a general role for Yap in anti-tumor T 
cell responses.  
 
Figure 3.5. T cell specific deletion of Yap results in reduced tumor growth 
and enhanced T cell tumor infiltration. Mice were challenged subcutaneously 
with B16F10 or LLC cells on the right flank. Some mice carrying B16F10 tumors 
received adoptive cell transfer of WT and Yap-cKO CD8+ T cells. Tumor growth 
was monitored over the course of 15 days, until the maximum size of the tumors 
reached 500mm3. B16F10 tumors were harvested for immunofluorescence or flow 
cytometric analysis. Statistical differences were determined by using a Student’s 
t-test. A. B16 tumor growth curve of WT and Yap-cKO mice (n=9/group). B. Tumor 
weight of B16 tumors derived from WT and Yap-cKO mice on Day 15 post injection 




n=5/cKO group). D. Tumor weight of LLC tumors derived from WT and Yap-cKO 
mice on Day 15 post injection (n=7/WT group, n=5/cKO group). E. CD8+ T cell 
immunofluorescence on day 15 of B16 tumor growth. F. Absolute numbers of CD3+ 
TILs from WT and Yap-cKO B16 tumors. Tumors were harvested on Day 15, 
stained with antibodies against CD45, CD3, CD4 and CD8 and analyzed using 
flow cytometry (n=5/WT mice, n=4/ Yap-cKO mice). G. Absolute numbers of CD4+ 
TILs from WT and Yap-cKO B16 tumors, prepared as in Fig4D (n=5/WT mice, n=4/ 
Yap-cKO mice). H. Absolute numbers of CD8+ TILs from WT and Yap-cKO B16 
tumors, prepared as in Fig4D (n=5/WT mice, n=4/ Yap-cKO mice). I. Experimental 
plan for adoptive cell transfer of WT and Yap-cKO CD8+ T cells in WT B16 bearing 
mice. J. Absolute numbers of dTom+ and EYFP+ WT vs Yap-cKO CD8+ T cells in 
C57BL/6 B16 tumors. WT dTom+ CD8+ T cells were mixed 1:1 with Yap-cKO 
EYFP+ CD8+ T cells prior to being injected into WT C57BL/6 mice. Subsequently, 
mice were injected subcutaneously with B16F10 melanoma cells and absolute 
number of infiltrating T cells was determined on D15 by flow cytometry (n=5/group). 
K. Percentage of dTom+ and EYFP+ CD8+ T cells out of total B16 tumor infiltrating 
CD8+ T cells (n=5/group). 
 
Given the strong correlation between CD8+ T cell tumor infiltration and 
patient survival, and CD8+ T cell tumor infiltration and patient responses to 
immunotherapy [33-38, 160-163], we investigated the extent of T cell infiltration in 
tumors that developed in WT versus Yap-cKO mice. Immunofluorescence 
microscopy analysis revealed that tumors from Yap-cKO mice were significantly 
more infiltrated with CD8+ T cells at both the tumor center and tumor edge 
compared to WT mice (Figure 3.5E). Flow cytometry revealed more Yap-cKO 
CD4+ and CD8+ T cells infiltrated tumors compared to WT counterparts (Figure 
3.5F-H).  
To directly address whether Yap-deleted T cells have an increased ability 
to infiltrate tumors, we isolated polyclonal CD8+ T cells from Yap-cKO and WT 
mice and directly compared tumor infiltrating T cell numbers  in adoptive transfer 




3.5I). We isolated tdTomato+ CD8+ T cells from WT mice and EYFP+ CD8+ T cells 
from Yap-cKO mice and mixed them at a 1 to 1 ratio. Cell mixtures were 
intravenously injected into WT mice the same day as subcutaneous injection of 
B16F10 cells. Absolute numbers of tdTomato+ (WT) and EYFP+ (Yap-cKO) CD8+ 
T cells were then measured in tumors after 15 days. Yap-cKO CD8+ T cells showed 
a significantly enhanced capacity to infiltrate tumors (Figure 3.5J), with nearly 30% 
of all CD8+ tumor-infiltrating T cells being EYFP+ Yap-cKO T cells compared to 
almost undetectable numbers of tdTomato+ WT T cells (Figure 3.5K). These data 
are the first to conclusively show that Yap-cKO CD8+ T cells have intrinsic 
enhancement of their tumor infiltration capacity. 
 
Yap regulates global T cell responses in the local tumor microenvironment. 
We next aimed to define Yap-regulated signaling networks in T cells that 
impacted tumor growth and T cell infiltration. CD4+ and CD8+ TILs were isolated 
from B16 tumors grown in WT or Yap-cKO mice, as well as CD4+ and CD8+ T cells 
from corresponding TDLNs and analyzed by RNA-Seq. Many genes were 
differentially expressed in CD4+ and CD8+ TILs isolated from Yap-cKO mice 
compared to WT mice (Figure 3.6A-B and 3.7A-B). Notably, T cells from TDLNs 
showed markedly fewer gene expression changes with Yap deletion when 
compared to TILs (Figure 3.6C-D). These data are consistent with Yap function 




responses observed in Yap-cKO T cells are mediated by changes in cellular 





Figure 3.6. RNA-Seq analysis of Yap-cKO CD4+ and CD8+ B16 TILs uncovers 




A. WT vs Yap-cKO CD4+ TIL DEG heatmap. B. WT vs Yap-cKO CD8+ TIL DEG 
heatmap. C. WT vs Yap-cKO CD4+ TDLN DEG heatmap. D. WT vs Yap-cKO CD8+ 
TDLN DEG heatmap. E. Hyper-enrichment analysis shows enrichment of induced 
gene sets observed in CD4+ Yap-cKO TILs. F. Hyper-enrichment analysis shows 
enrichment of induced gene sets observed in CD8+ Yap-cKO TILs. G. Hyper-
enrichment analysis shows enrichment of repressed gene sets observed in CD4+ 
Yap-cKO TILs. H. Hyper-enrichment analysis shows enrichment of repressed 
gene sets observed in CD8+ Yap-cKO TILs. I. Gene expression changes identified 
in Yap-cKO CD4+ and CD8+ TILs correlate with genes reflecting tumor infiltration 
across many cancers in TCGA data. The heatmap is colored by the coefficient and 
the text of each cell represents the adjusted p-value of the correlation. J. Gene 
expression changes identified in Yap-cKO CD4+ and CD8+ T cells correlate with 
patient survival data available in TCGA across several cancers. Blue: the average 
survival probability for patients with low activity of the signature is higher. Red: the 
average survival probability for patients with high activity of the signature is higher. 
Yellow: neither group has a higher probability of survival. The text of each cell is 
the p-value for the survival estimation. The distribution of p-values arising from the 
multiple survival analyses for each signature across TCGA datasets was 
compared to a uniform distribution using a Kolmogorov-Smirnov test. K. Kaplan-
Meier Survival analysis showing the average survival probability of patients with 
lung adenocarcinoma that show low versus high Yap activity derived from the Yap-
cKO CD4+ gene expression signature. L. Kaplan-Meier Survival analysis showing 
the average survival probability of patients with lung adenocarcinoma that show 







Figure 3.7. Top 25 upregulated and downregulated genes with Yap deletion 
in CD4+ and CD8+ TILs. A. WT vs Yap-cKO CD4+ TILs top and bottom DEG 
heatmap. B. WT vs Yap-cKO CD8+ TILs top and bottom DEG heatmap. 
 
Hyper-enrichment analyses [164] of gene expression changes identified in 
TILs from Yap-cKO mice showed induction of genes related to T cell activation, 
differentiation, survival and migration (Figure 3.6E-F), implicating Yap in 
fundamental T cell processes beyond those previously reported. Yap-cKO TILs 
showed enrichment of genes associated with TCR signaling, genes that encode 
major co-stimulatory molecules, and genes downstream of TCR signaling (Figure 
3.8A-B), suggesting enhanced responsiveness to TCR signals and consistent with 




also enriched in Yap-cKO TILs, suggesting that cytokine production and 
responsiveness to cytokine receptor engagement were enhanced. Further, 
chemokine and chemokine receptor signaling gene sets were enriched in Yap-cKO 
TILs (Figure 3.8C-F), which likely contributes to their improved tumor infiltrating 
capacities. Subset defining transcription factors and cytokines associated with 
each of the major CD4+ T cell phenotypes were all upregulated in Yap KO CD4+ 
TILs (Figure 3.8G-H), suggesting that Yap deletion leads to enhanced naive CD4+ 
T cell differentiation, consistent with our in vitro observations. Using unique 
upregulated genes after differentiation to each of the major T helper subsets [165], 
analysis of our data showed that Yap-cKO CD4+ TILs are more skewed towards a 
Th2 and Treg phenotype compared to WT CD4+ TILs (Figure 3.9A-D), consistent 
with prior studies showing that the B16F10 tumor microenvironment enhances 
these fates [166-168]. As expected, gene set enrichment profiles identified in Yap-
cKO TILs also included “Yap1 and TAZ stimulated gene expression” and “signaling 
by Hippo”, which were repressed in both CD4+ and CD8+ TILs (Figure 3.8G-H). 
An unbiased analysis of transcription factor binding motifs in upstream regulatory 
regions of the genes altered in Yap-cKO CD4+ and CD8+ TILs revealed the TEAD 
transcription factor motif as the most significantly enriched in both cell populations 
(Figure 3.10A-B), suggesting that Yap-regulated TEAD activity contributes to 






Figure 3.8. Expression of genes related to T cell activation and co-
stimulation, chemokines and chemokine receptors, T helper subset defining 
cytokines and transcription factors are upregulated in Yap-cKO CD4+ and 




genes in WT versus Yap-cKO CD8+ TILs. B. Log10(normalized RNA-Seq counts 
+1) of T cell activation related genes in WT versus Yap-cKO CD4+ TILs. C. 
Log10(normalized RNA-Seq counts +1) of chemokine genes in WT versus Yap-
cKO CD8+ TILs. D. Log10(normalized RNA-Seq counts +1) of chemokine receptor 
genes in WT versus Yap-cKO CD8+ TILs. E. Log10(normalized RNA-Seq counts 
+1) of chemokine genes in WT versus Yap-cKO CD4+ TILs. F. Log10(normalized 
RNA-Seq counts +1) of chemokine receptor genes in WT versus Yap-cKO CD4+ 
TILs. G. Log10(normalized RNA-Seq counts +1) of T helper subset defining 
cytokines in WT versus Yap-cKO CD4+ TILs. H. Log10(normalized RNA-Seq 
counts +1) of T helper subset defining transcription factors in WT versus Yap-cKO 
CD4+ TILs. Significant differences were determined by a Student’s t test; *, p<0.05; 







Figure 3.9. Yap-cKO vs WT CD4+ TILs are skewed towards TH2 and Treg 
signatures compared to WT. A. Heatmap of statistically significant differentially 




significant differentially expressed TH2 genes in WT vs Yap-cKO CD4+ TILs. C. 
Heatmap of statistically significant differentially expressed TH17 genes in WT vs 
Yap-cKO CD4+ TILs. D. Heatmap of statistically significant differentially expressed 




Figure 3.10. The TEAD binding motif is enriched in upstream regulatory 
elements found in gene altered in expression within Yap-deleted TILs. 
HOMER de novo motif analysis was performed on down-regulated gene 
expression changes identified in Yap-deleted A. CD4+ and B. CD8+ TILs, revealing 
the TEAD transcription factor motifs among the top enriched motifs. 
 
Comparison of gene expression changes identified in CD4+ and CD8+ Yap-
cKO TILs with clinical data from TCGA [169] showed significant correlation of gene 
signatures with T cell infiltration across a variety of human cancers (Figure 3.6I). 
Consistent with our preclinical results in melanoma (B16F10) and lung cancer 




melanoma (SKCM), lung squamous cell carcinoma (LUSC), and lung 
adenocarcinoma (LUAD). Genes altered in Yap-cKO TILs were also significantly 
associated with patient survival across several cancers (Figure 3.5J), as seen 
most significantly in LUAD for both CD4+ and CD8+ Yap-cKO gene signatures 
(Figures 3.5K-L). These analyses showed that increased Yap activity in TILs 
correlated with poorer prognosis and lower T cell infiltration, suggesting that Yap 
function in T cells contributes to aggressive human cancer development and 
cancer immunosuppression.  
 
3.4 Conclusions and Future Directions 
We present evidence for an immune inhibitory role for Yap in both CD4+ 
and CD8+ T cells, and offer the first data showing Yap is a direct negative regulator 
of T cell tumor infiltration. We found that disrupting Yap activity leads to enhanced 
T cell activation, augmented differentiation, and increased tumor infiltration. Two 
major signals are necessary for T cell activation: signaling from engagement of the 
TCR with its cognate antigen:major histocompatibility (MHC) complex, and a 
second signal from the co-stimulatory receptor CD28 binding to ligands CD80 and 
CD86 [21, 170]. Experimental data indicated that CD4+ and CD8+ T cells from Yap-
cKO mice were more sensitive to TCR signaling compared to WT cells. We 
demonstrated significant upregulation in sensitivity of activation markers CD44, 
CD25, and CD69 to TCR signal strength. Through recruitment of key effector 




induced by TCR signaling that lead to production of cytokines and cytokine 
receptors, which importantly include IL-2 and CD25, the α chain of the 
heterotrimeric high-affinity IL-2 receptor. IL-2 binding to the IL-2 receptor, together 
with TCR signaling and co-stimulation elicit transcriptional changes resulting in 
proliferation and differentiation [171]. RNA-sequencing analysis of WT vs Yap-cKO 
TILs revealed that CD3, CD28, CD80 and CD86 receptor molecules, kinases, 
phosphatases, and scaffold proteins are all upregulated with Yap deletion, offering 
a mechanism for enhanced activation of CD4+ and CD8+ T cells. These 
mechanisms are significantly broader in scope than the TGFβ-specific 
mechanisms previously reported for Yap in Tregs [140], implicating Yap as a 
regulator of all activated T cell responses.  
Our analysis of thymic populations provides the first conclusive evidence 
that Yap deletion does not cause significant changes in thymocyte maturation. 
These data suggest the function of Yap is primarily in mature T cells, and loss of 
Yap is not deleterious to thymocytes. While the precise reason for differential 
action of Yap in thymocytes versus mature T cells remains undefined, other 
proteins have distinct TCR-induced mechanisms in immature thymocytes 
compared to mature T cells. For example, Nur77 is less pro-apoptotic in mature T 
cells compared to thymocytes due to differences in TCR-induced phosphorylation 
and kinase activity [172]. We did observe a slight increase in total number of 
TCRβ+CD69+ thymocytes in Yap-cKO mice compared to WT mice. This increase 




Yap enhances T cell sensitivity to TCR signaling. Interestingly, we did not see a 
corresponding increase in numbers of Yap-cKO T cells at later maturation stages, 
suggesting that the increased numbers of positively selected thymocytes may not 
survive negative selection. All other analyses from our studies indicated the Yap-
cKO mice are developmentally equivalent to WT mice, implicating Yap as post-
developmental regulator of T cells. 
We demonstrated that Yap-cKO enhanced CD4+ and CD8+ T cell activation 
in vitro. Observed increases in TEAD1 and TEAD3 expression in activated T cells 
suggest that Yap may exert its immunosuppressive effects through TEAD-
regulated transcription. Consistent with this idea, TEAD-binding motifs were the 
most enriched motif in the Yap-regulated gene expression signature identified in 
Yap-cKO TILs. Further, treatment with verteporfin, a reported inhibitor of Yap-
TEAD activity [145], increased T cell activation similar to Yap-deletion. 
Interestingly, neither Yap deletion nor verteporfin treatment significantly impacted 
T cell proliferation. These observations are consistent with observations of 
increased early activation markers in Yap inhibited cells. Previous studies have 
demonstrated proliferation has a sharp, switch-like threshold for TCR signal to elicit 
proliferation [173], and our experimental conditions provided optimal signaling 
above this threshold. Expression levels of activation markers have been directly 
linked to TCR signal strength, such as CD69 levels being directly regulated by 
affinity and dose of TCR ligand [174] and CD71 levels being directly linked to 




conceptual advance, which is that Yap may link TCR signal strength to negative 
feedback. 
The rapid induction of Yap post-T cell activation implicates shared canonical 
signals of T cell activation in the regulation of Yap. These observations are 
consistent with those made previously in naïve CD8+ T cells [130], but contrast 
those arguing  Treg specific roles for Yap [140]. Our data suggest that Yap 
promotes a normal negative feedback mechanism during T cell activation similar 
to inhibitory checkpoint molecules, and inhibition of Yap must be timed before or 
during T cell activation. Our observations interestingly also indicate that Yap plays 
a prominent role only following activating signals from the microenvironment. This 
is highlighted by the large number of genes impacted in Yap-deleted CD4+ and 
CD8+ T cells isolated from TILs compared to few genes differentially expressed in 
TDLNs, and is consistent with our data showing Yap levels increase after T cell 
activation. These data suggest that therapeutic inhibition of Yap in T cells may 
have fewer side effects compared to strategies such as checkpoint blockade, since 
the regulatory activity of Yap is synchronized with T cell activation and appears 
specific to sites of active T cell priming. Yap connects a variety of extracellular 
stimuli into intracellular cues that informs the cell of its own structural features 
(actin cytoskeleton, polarity, cell shape) as well as its location and surroundings 
(mechanical, adhesion, ECM), instructing cellular survival, proliferation, 




by these signals in T cells may reveal new insights into immunoregulatory 
mechanisms.  
Regulation of T cell activation by the microenvironment through polarizing 
cytokines allows for diverse, context-specific differentiation and functional diversity 
in CD4+ T cells [22]. We observe that Yap-cKO CD4+ T cells have increased 
capacity to differentiate towards Th1, Th2, Th17, and Treg phenotypes, implicating 
Yap in roles beyond those described by previous studies. Our observations 
indicate that Yap does not preferentially bias control of T cell differentiation, but 
instead enhances responsiveness to local microenvironmental cuesOverall, our 
data suggest that Yap inhibition may enhance responses to current 
immunotherapy strategies. Clues into Yap-regulated events are embedded in our 
RNA-Sequencing of Yap-cKO TILs, which show broad changes in T cell 
responses. Genes regulated by Yap include several key effectors of T cell 
activation, including genes in T cell receptor signaling pathways NFKB, MAPK and 
NFAT, and those controlling JAK-STAT signaling that modulate the polarization of 
naïve CD4s into T helper subsets [176]. Notably, Yap-regulated genes are also 
enriched for those regulated by the TGFβ and Wnt pathways, which have important 
pleotropic roles in T cell biology [177, 178]. Given the known convergence of Yap 
with these immunomodulatory pathways [179], it is likely Yap directs their 
transcriptional targets and signal strength. Our study provides novel evidence of 





An important finding of our studies is that Yap-cKO mice show delayed 
tumor growth in conjunction with increased infiltration and expression of effector 
molecules. The well-characterized B16F10 melanoma and LLC lung cancer 
models generate tumors that are characterized as immune deserts [156-159, 180-
182]. In immune deserts, T cells are completely excluded from the tumor 
microenvironment due to suppressed tumor immunogenicity and insufficient T cell 
priming, co-stimulation, and activation [31].  Patients with immune desert tumors 
show reduced survival, and are not responsive to immune checkpoint inhibitor (ICI) 
strategies. The ability for Yap-cKO CD4+ and CD8+ T cells to become activated 
and infiltrate tumors that normally inhibit T cell infiltration  is therefore remarkable 
and important, as these phenotypes are key for combating tumor growth in human 
cancer patients [183]. Adoptive transfer of Yap-cKO CD8+ T cells showed that 
CD8+ T cells have intrinsically enhanced tumor infiltration capacity compared to 
WT host CD8+ T cells into B16F10 tumors. These data are novel and suggest that 
one of the early events in Yap-mediated tumor immunosuppression may be 
exclusion of CD8+ T cells from the tumor. In mice with Yap-cKO T cells, tumor cell 
killing by early infiltration of CD8+ T cells may elicit 1) tumor antigen release for 
enhanced intratumoral T cell priming and 2) increased intratumoral activation of 
CD8+ T cells, causing chemokine secretion and recruitment of CD4+ T cells and 
other immune cells. These data provide a new conceptual framework for the 
sequence of immunosuppressive events orchestrated by Yap in tumors, and 




significant correlation of CD8+ and CD4+ Yap-cKO gene signatures with tumor T 
cell infiltration in TCGA data suggest that Yap represses CD8+ and CD4+ T cell 
migration and tumor infiltration in human cancers. In particular, our preclinical 
results in melanoma and lung cancer models were mirrored in human SKCM, 
LUAD, and LUSC. Low activity of Yap-regulated CD4+ and CD8+ gene expression 
signatures correlated with immune infiltration in 19 TCGA cancer types, and 
strongly correlated with survival in 11 TCGA cancer types, highlighting Yap activity 
in T cells has broad potential as a target for cancer therapy.  
Collectively, our data show that Yap is an important immunosuppressor and 
suggest that inhibition of Yap activity in T cells could have important clinical 
implications in T cell therapies against cancer and other diseases. We integrate 
findings from prior studies and extend them, showing for the first time that Yap is 
expressed in activated CD4+ and CD8+ T cells and plays a regulatory role in T cell 
activation for both subsets. Insights from our study motivate future investigation of 
Yap inhibition to enhance anti-tumor responses and on the broader role and 
mechanisms of Yap in regulating T cells in homeostasis and disease. 
 
3.5 Materials and Methods 
 
Mouse Strains and Genotyping 
Yap-loxP/loxP mice provided by Dr. Jeff Wrana and previously described 
[184] were backcrossed to the C57BL/6 background for 10 generations, and bred 




lines to derive Yap-loxP/loxP; LSL-EYFP; CD4-Cre mice. For adoptive cell 
transfers, CD4-cre mice were crossed with LSL-tdTomato mice (Jax: 007914) 
[187]. All experiments were performed with 6-10 weeks old mice. Animal protocols 
and study designs were approved by Boston University School of Medicine and 
UMBC. Mice were maintained in pathogen-free facilities at BUMC and UMBC and 
were PCR genotyped using published protocols [184-187]. 
 
Cell culture and mouse tumor challenges 
B16F10 mouse melanoma cells (ATCC CRL-6475) and LLC1 Lewis lung 
carcinoma cells (ATCC CRL-1642) were cultured in DMEM supplemented with 
glucose, L-glutamine, sodium pyruvate, 10% FBS, penicillin and streptomycin. 
Cells were split once they reached 70% confluency and were not used for mouse 
challenge past a fifth passage. T cells were cultured in RPMI 1640 supplemented 
with 10% FBS, 1 mM sodium pyruvate, 50 μM β-ME, penicillin, streptomycin, 2 
mM L-glutamine, 100 mM non-essential amino acids, 5 mM HEPES free acid and 
-mercaptoethanol. For tumor inoculations, 5x104 B16F10 cells or 5x105 LLC cells 
were injected subcutaneously on the right flank of each mouse on day 0. Tumor 
volume was estimated using the formula (L × W2)/2. Survival endpoint was 
reached once the tumors measured 500mm3, around day 15. Mice were 
euthanized by isoflurane inhalation and subsequent cervical dislocation and 





T cell isolation 
Spleens from WT or Yap-cKO mice were pushed through a 70µm mesh 
(Falcon) using an insulin syringe plunger and washed with PBS. Cells were treated 
with ACK red blood cell lysis buffer and splenocyte single cell suspensions were 
prepared for magnetic separation or stained for sorting by flow cytometry. CD4+ or 
CD8+ T cell enrichment was performed using magnetic beads (Miltenyi Biotec or 
STEMCELL Technologies). Naïve CD4+ T cells were isolated using a naive CD4+ 
T cell isolation kit (Miltenyi Biotec). 
 
Flow cytometry  
Isolated splenocytes or tumor digests were washed with PBS and stained 
with the LIVE/DEAD fixable near-IR dead cell stain kit (Invitrogen). Cells were then 
washed with stain buffer (BD), resuspended in stain buffer containing Fc block 
(BD) and incubated for 5 minutes at 4C. Surface antibodies were added in 
predetermined concentrations and cells were incubated for 30 minutes at 4C or 
15 minutes at room temperature, before being washed with BD stain buffer and 
resuspended in PBS for flow cytometric analysis. For intracellular cytokine 
staining, cells were fixed and permeabilized using the BD Cytofix/Cytoperm 
Fixation/Permeabilization kit (BD) after dead cell dye and surface staining. For 
transcription factor staining, the eBioscience Foxp3/ Transcription factor staining 
buffer set was used. Flow cytometry analyses were performed on BD LSRII at 




of Maryland School of Medicine Center for Innovative Biomedical Resources, Flow 
Cytometry Shared Service and analyzed by FlowJo (TreeStar). 
 
T cell activation and proliferation assays 
Cells were cultured and stimulated in 96 well plates at 1x105 cells per well. 
Plates were coated with anti-CD3 antibody (Biolegend) at concentrations of 0, 
0.125, 0.25, 0.5, and 1μg/ml at 4°C overnight, and were washed twice with PBS 
before incubation. Cells were stimulated in the anti-CD3 bound plates with soluble 
anti-CD28 at 2 μg/ml (Biolegend). On days 1 and 3, cells were stained with dead 
cell dye as well as lineage and activation markers CD3 BUV737 (BD), CD4 
BUV395 (BD), CD8 PerCP-Cy5.5 (Biolegend), CD69 PE (Biolegend), CD44 
BV650 (Biolegend), and CD25 APC (Biolegend). For proliferation assays, CD4+ or 
CD8+ T cells were isolated and stained using the CellTrace Violet or CFSE Cell 
Proliferation Kit (Life Technologies). Briefly, purified cells were washed with 
PBS and incubated with CellTrace dye for 20 minutes at 37C protected from 
light. After 20 minutes, complete RMPI medium was added to the cell 
suspension and the cells were incubated 5 minutes further before being 
washed and resuspended in complete RPMI medium. Cells were cultured in 
96 well plates at 1x105 cells per well and were stimulated using CD3/CD28 
dynabeads (Gibco) at a 1:1 ratio with T cells. On days 1 and 3, cells were stained 





CD4+ T cell in vitro differentiation 
For CD4+ T cell in vitro differentiations into Th1, Th2, Th17 and Treg 
subsets, naïve CD4+ T cells were enriched using magnetic beads (Miltenyi Biotec). 
Purified cells were plated at 1x105 cells per well on a 96 well plate coated with 
10g/ml CD3 (Biolegend), and cultured with 2g/ml soluble CD28 (Biolegend). 
The following conditions were specific to each differentiation regime: Th1, 10ng/ml 
IL-12 and 10g/ml IL-4; Th2, 50ng/ml IL-4, 10g/ml IFN and 10g/ml IL-12; 
Th17, 50ng/ml IL-6, 20ng/ml IL-1, 5ng/ml IL-23, 1ng/ml TGF, 12g/ml IFN and 
10g/ml IL-4; Treg, 100IU/ml IL-2, and 0, 0.5 or 5ng/ml TGF. Cytokines and 
antibodies were purchased from Biolegend, except for IL-2 and TGF (R&D). Cells 
were cultured for 5 days, before being stimulated with 50ng/ml PMA (Sigma, 
P1585) and 1g/ml ionomycin (Sigma, I0634) for 6 hours at 37 °C in the presence 
of Golgistop (monensin, BD) or Golgiplug (brefeldin, BD) added after the first 30 
minutes of stimulation. Cells were stained with the LIVE/DEAD fixable near-IR 
dead cell stain kit (Invitrogen), surface markers CD3 BUV737 (BD), CD4 BUV395 
(BD), CD8 APCFire750 (Biolegend) and CD25 BV510 (Biolegend), intracellular 
cytokines IFN APC (Bioleged) and IL-17 PerCP-Cy5.5 (Biolegend) or transcription 
factors GATA3 PECy7 (Biolegend) and Foxp3 PE (BD), as described above. 
 
Thymocyte phenotyping 
Thymuses from WT or Yap-cKO mice (8-10 weeks old) were mechanically 




plunger and washed with PBS. Cells were treated with ACK red blood cell lysis 
buffer and thymocyte single cell suspensions were stained for analysis by flow 
cytometry as described above. Cells were stained with dead cell dye and the 
following surface antibodies: CD3 BUV737 (BD), CD4 BUV395 (BD), CD8 PerCP-
Cy5.5 (Biolegend), TCR BV510 (Biolegend), CCR7 PECy7 (Biolegend), H-2Kb 
PE (Biolegend), CD69 BV421 (Biolegend), CD45R/B220 APCFire750 (Biolegend), 
CD25 APCFire750 (Biolegend), GL3 APCFire750 (Biolegend) and NK1.1 
APCFire750 (Biolegend). Thymocytes were also stained intracellularly with Nur77 




B16 tumors from WT and Yap-cKO mice were dissected, mechanically 
disrupted and digested in serum free media containing 2mg/ml collagenase type I 
(Worthington) and DNase I (Sigma) for 30 minutes at 37C in a rotator. Tumor 
digests were then passed through a 70µm mesh (Falcon) using an insulin 
syringe plunger and washed with PBS. Cells were treated with ACK red blood cell 
lysis buffer (Gibco) and tumor single cell suspensions were prepared for staining 
and analysis by flow cytometry, using the following reagents: CD45 BV510 
(Biolegend), CD3 BUV737 (BD), CD4 BUV395 (BD), CD8 PerCP-Cy5.5 




infiltrating T cells by flow cytometry, AccuCount fluorescent particles (Spherotech) 
were added to the tumor digests. 
 
Adoptive cell transfers 
For the adoptive cell transfers, EYFP+ Yap-cKO CD8+ T cells were mixed 
1:1 with dtTomato+ WT CD8+ T cells and injected intravenously into 8-week-old 
WT C57BL/6 mice (Taconic) on day 0. Mice also received a subcutaneous injection 
of 5x104 B16F10 cells on the same day. On day 15 of tumor growth, tumors were 
harvested and stained with dead cell dye (DAPI, Biolegend), CD45 BV510 
(Biolegend), CD3 BUV737 (BD), CD4 APC (Biolegend) and CD8 PerCP-Cy5.5 
(Biolegend) antibodies for flow cytometric analysis.  
 
Immunofluorescence microscopy 
Harvested B16 tumors were fixed overnight in PLP fixative, followed by 
incubation in 15% and 30% sucrose. Tumors were embedded in OCT and frozen. 
Cryosections were cut at 5m thickness and stored at -20C. On the day of 
staining, slides were air dried for 1 hour and fixed in acetone for 10 minutes. 
Slides were washed with PBS and blocked with PBS containing 10% donkey 
serum, 0.05% sodium azide, 0.5% triton X-100 and 0.2% BSA for 1 hour at 
room temperature. Slides were stained with rat anti-mouse CD8 (clone CT-
CD8a, Fisher) for 2 hours at room temperature, and were subsequently 




blocking buffer and applied for 1 hour at room temperature (donkey anti-rat 
alexa 647, Jackson Immuno Research Labs). Slides were washed and 
mounted in ProLong antifade reagent with DAPI (Life Technologies). Images 
were acquired using an AxioObserver D1 equipped with a X-Cite 120LED 
System. 
 
Immunoblotting and Quantitative real-time PCR (qPCR) 
RNA was extracted using Rneasy Mini Kit (Qiagen), and 1g was used to 
generate cDNA using an iScript cDNA Synthesis Kit (Biorad). Taqman primers 
(Life Tech) for mouse Gapdh (4352339E), Yap (Mm01143263_m1) or TEAD1-4 
(Mm00493507_m1,  Mm00449004_m1, Mm00449013_m1, Mm01189836_m1) 
were mixed with cDNA and Taqman Universal Master Mix II (Life Tech) and ddCT 
values were calculated relative to unstimulated controls. Protein lysates were 
analyzed by immunoblotting with anti-YAP (D8H1X) XP (CST 14074) and anti-
GAPDH (D16H11) XP (CST 8884) antibodies (original immunoblot images as 
shown in Supplementary Data 5), and imaged using a Bio-Rad ChemiDoc 
system. 
 
Sample preparation for RNA-Seq  
B16 tumors from WT and Yap-cKO mice were digested as described above. 
Tumors were subsequently stained with CD45 V500, CD3 PE, CD4 APC, CD8 




from each tumor using a BDFACSARIA instrument. CD4+ and CD8+ T cells were 
sorted from WT and Yap-cKO tumor draining lymph nodes, as well. Cells were 
sorted into TRIzol LS reagent (Invitrogen) and RNA was isolated using a 
miRNeasy micro kit (Qiagen).  
 
Transcriptomic analyses and gene expression signature extraction 
RNA quality was evaluated using Agilent Bioanalyzer 2100 Eukaryote Total 
RNA Pico chips. RNA-Seq libraries were prepared using the SMART-Seq v4 Ultra 
Low Input RNA Kit (Takara, 634889) from total RNA, following the manufacturer’s 
protocol. Libraries were then sequenced on a HiSeq 4000 using 75-bp paired end 
reads to an average depth of 22,445,650 ± 240,398 reads (SEM). Transcript 
abundance estimates were quantified using Salmon to mouse reference 
transcriptome from assembly GRCm38 (mm10), aggregated to gene level for 
UCSC-annotated genes using tximport, and DESeq2 was used to calculate 
normalized counts and differential expression [188, 189]. CD4 and CD8 up/down 
gene signatures were generated through differential expression analysis via 
DESeq2. Differentially expressed genes (DEG) between CD4 vs. WT and CD8 vs. 
WT were defined as log2(FC) > 1 (up) or log2(FC) < -1 (down) and FDR < 0.05. 
The top 25 differentially expressed genes for CD4+ and CD8+ T cells were 
visualized with a heatmap combined with a barplot annotation. The heatmap cells 
represent the log normalized expression values for each sample and include the 




a bar representing the log-fold change in gene expression (KO/WT). Plots were 
generated using the ComplexHeatmap software package available in R. The data 
discussed in this publication have been deposited in NCBI's Gene Expression 
Omnibus and are accessible through GEO Series accession number GSE139883  
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139883). 
 
Analysis of gene expression signatures in TCGA datasets 
The activation of CD4/8 up/down signatures was calculated with Gene Set 
Variation Analysis (GSVA) [190] in primary tumor samples across multiple TCGA 
RNA-Seq datasets. Signature activation was summarized by the sum of activation 
of the upregulated signature and inactivation of the downregulated signature. For 
example, CD4sig activity = GSVA(CD4up sig) – GSVA(CD4down sig). Heatmaps for all 
TCGA analyses were generated with the pheatmap software package available in 
R. TCGA data includes count matrices generated with STAR2/HTSeq downloaded 
from Genomic Data Commons (GDC) Data Portal. Each count matrix was 
normalized by relative log expression (RLE) with DESeq2. This analysis was 
constrained to samples where survival information was available and immune 
infiltration could be estimated with Tumor Immune Estimation Resource (TIMER) 
[191]. The average T Cell infiltration per sample was estimated with TIMER in each 
TCGA dataset, represented as a single heatmap cell. This average was measured 




were summed to observe their additive effect. Transcription factor motif analysis 
was performed using the HOMER de novo motif analysis tool [192]. 
For correlation of signatures with T cell infiltration, CD4/8 signature 
activation was correlated with the sum of CD4+ T cell and CD8+ T cell infiltration in 
each TCGA dataset estimated by TIMER [191]. The heatmap is colored by the 
correlation coefficient and the text of each cell is the adjusted p-value of the 
correlation. For survival analysis, the CD4/8 signature activation was used to 
stratify patients across TCGA datasets into high or low activated groups separated 
by the mean. For each data set, Kaplan-Meier survival plots were generated and 
the results were summarized with a heatmap. The color of each cell corresponds 
to the following categories. Dark blue in the graphs signifies the average survival 
probability for patients with low activity of the signature is higher while red signifies 
the average survival probability for patients with high activity of the signature is 
higher. Light blue and light orange signify the same groups with higher survival 
probability respectively, however the difference is not significant. The text of each 
cell is the p-value for the survival estimation. The distribution of p-values arising 
from the multiple survival analyses for each signature across TCGA datasets was 





CHAPTER 4: YAP AND TAZ INHIBIT CD4+ AND CD8+ RESIDENT AND 
EFFECTOR MEMORY T CELL DIFFERENTIATION 
 
4.1 Abstract 
 Memory T cells are crucial for the establishment of protective immunity. 
Understanding the molecular basis of their development is critical for vaccine 
design and immune based cancer therapies. We have previously shown that 
transcriptional regulator YAP represses primary T cell responses and effector T 
cell differentiation. Here, we show that YAP and TAZ, a YAP paralog, inhibit 
memory T cell generation upon viral and bacterial infection. T cell specific 
YAP/TAZ deletion leads to increased infiltration of activated CD8+ T cells, as well 
as resident and effector memory CD8+ T cells in the lungs of influenza infected 
mice. Similarly, YAP/TAZ deletion in T cells results in increased proportions of 
activated, resident and effector memory CD4+ T cells in pneumococcus infected 
mouse lungs. Overall, our data show that YAP/TAZ deficiency results in increased 
activated T cell infiltration at the site of infection and improves memory T cell 
generation, and suggest that YAP/TAZ inhibition can improve vaccine outcomes. 
 
4.2 Introduction 
 Memory T cells have the ability to remember past encounters with bacteria, 
viruses -and even tumor cells- long after primary exposure and mount a rapid, 




cell [45, 193-195]. Naïve T cells have never responded to a pathogen, but once 
they recognize their cognate antigen, they become activated, clonally divide and 
differentiate into effector T cells that migrate to inflamed areas and kill infected 
cells [45]. This response reaches its peak of clonal expansion by the second week 
of infection, after which point pathogen is eliminated, and most effector cells die, 
leaving only a small pool of long-lived memory T cells behind. These memory cells 
can rapidly expand and secrete effector molecules if reinfection occurs, conferring 
the organism with protective immunity. Anti-viral, anti-bacterial and anti-tumor 
vaccines induce T cell memory, thereby generating long-lasting immunity against 
the target [196, 197]. In addition, a memory phenotype is beneficial for the efficacy 
of CAR-T cells as a cancer therapy [198]. Therefore, understanding how 
immunological memory is established can help improve vaccine development 
against infectious disease and cancer therapy.  
 There are several memory T cell subsets, including central memory (TCM), 
effector memory (TEM) and resident memory (TRM), with the origin of this 
heterogeneous pool of memory T cells being the subject of extensive study [44, 
45, 199, 200]. In general, two paradigms predominate: memory T cells are derived 
from a subset effector T cells that have escaped cell death, or effector and memory 
T cells each stem from independent naïve T cell precursors [53, 201-203]. By 
studying DNA methylation patterns and chromatin accessibility, two recent studies 
provide compelling evidence that memory T cells originate from a subset of 




effectors, genes associated with the naïve state become hypermethylated, 
whereas methylation is downregulated at effector associated genes. Methylation 
marks on naïve associated genes are removed in effector T cells that are 
differentiating into memory T cells aiding in their long-term survival, and although 
expression of effector molecules is downregulated in these cells, chromatin is open 
at the sites of effector genes, allowing memory T cells to acquire effector functions 
rapidly upon re-infection [59, 61].  
 We have previously shown that transcriptional regulator YAP inhibits T cell 
activation and differentiation into effector subsets and T cell specific deletion leads 
to reduced tumor burden [112].  Intriguingly, we also found that YAP deficient 
tumor infiltrating lymphocytes (TILs) upregulate expression of genes associated 
both with effector differentiation and function, as well as with naïve, long-lived 
state. This finding was particularly interesting in light of the aforementioned studies 
revealing a role of both naïve and effector associated genes in memory T cell 
generation and function, as it suggests that YAP inhibition in T cells could lead to 
more efficient memory T cell differentiation. Given that TAZ, the paralog of YAP 
can compensate for YAP loss, we decided to generate a mouse model with 
conditional deletion of both genes and test whether YAP/TAZ inhibit memory T cell 
generation. We found that combined deletion of TAZ and YAP results in increased 
effector memory and resident memory T cell generation in mouse models of 
influenza and pneumococcus infection. In the influenza model, memory T cell 




whereas in the pneumococcus model the opposite was observed. Our findings 
provide evidence that YAP/TAZ inhibit memory T cell generation and warrant 
further work to determine the functionality of YAP/TAZ deficient memory T cells 
and the potential benefit of YAP/TAZ inhibition in vaccine development. 
 
4.3 Results  
YAP and TAZ inhibit CD8+ resident memory and effector memory T cell 
generation during influenza infection. 
 To study the role of YAP and TAZ in CD4+ and CD8+ memory T cell 
development we generated a mouse model whereby YAP and TAZ deletion are 
induced under the control of the CD4 promoter (YAP-loxP/loxP; TAZ-loxP/loxP; 
CD4-Cre, herein referred to as Y/T-cKO).  No systemic defects were observed in 
Y/T-cKO mice housed in a barrier facility, however significant differences in 
memory T cell generation were observed after infectious challenge. Briefly, wild 
type (WT) and Y/T-cKO were challenged with influenza virus strain PR8 and 6 
weeks later, their lungs were harvested for phenotypic analysis. 
 We found that a significantly higher proportion of CD45+ cells infiltrating the 
lungs of infected mice were CD8+ in the Y/T-cKO compared to WT, indicating 
increased CD8+ T cell infiltration in the lungs of knockout mice (Figure 4.1A). 
These CD8+ T cells also significantly upregulated CD69 in the Y/T-cKO compared 
to WT, indicating that the infiltrating T cells were more activated with TAZ and YAP 




marker CD44 and downregulated naïve T cell marker CD62L (Figure 4.1C, D). A 
significantly higher proportion of Y/T-cKO CD8+ T cells presented with an effector 
memory and resident memory phenotype compared to WT, whereas a significantly 
lower proportion of them had a naïve CD8+ T cell phenotype (Figure 4.1E-G). The 
lungs of Y/T-cKO mice were infiltrated with significantly higher numbers of 
CD8+CD69+ T cells, CD8+CD44+ T cells, CD8+CD44+CD62L- T cells (TEM) and 
CD8+CD44+CD62L-CD69+CD103+ T cells (TRM) T cells relative to WT (Figure 
4.1H-K). Even though the proportion of naïve T cells was significantly decreased 
in Y/T-cKO CD4+ T cells, we did not observe a change in absolute numbers of 
infiltrating cells, or memory phenotype (Figure 4.2). These results indicate that 
TAZ and YAP inhibit CD8+ T cell infiltration in influenza infected lungs, CD8+ T cell 






Figure 4.1. Increased CD8+ T cell activation, memory formation and 
infiltration in influenza infected lungs of YAP/TAZ-cKO mice. WT and 
YAP/TAZ-cKO mice were treated with saline or infected with influenza strain PR8 
and 6 weeks later, they were euthanized and their lungs were collected for 




using a Student’s t-test. A. Percent CD8+ of CD45+. B. Percent CD69+ of CD8+. C. 
Percent CD62L+ of CD8+.  D. Percent CD44+ of CD8+.  E. Percent CD44-CD62L+ 
of CD8+. F. Percent CD44+CD62L- of CD8+. G. Percent TRM of CD8+. H.  
CD8+CD69+ T cell counts. I.  CD8+CD44+ T cell counts. J.  CD8+ TEM counts. K.  






Figure 4.2. Lung influenza infection does not affect CD4+ memory T cell 
formation in YAP/TAZ-cKO mice. WT and YAP/TAZ-cKO mice were treated with 
saline or infected with influenza strain PR8 and 6 weeks later, they were 
euthanized and their lungs were collected for phenotypic analysis by flow 




Percent CD4+ of CD45+. B. Percent CD69+ of CD4+. C. Percent CD62L+ of CD4+.  
D. Percent CD44+ of CD4+.  E. Percent CD44-CD62L+ of CD4+. F. Percent 
CD44+CD62L- of CD4+. G. Percent TRM of CD4+. H.  CD4+CD69+ T cell counts. I.  
CD4+CD44+ T cell counts. J.  CD4+ TEM counts. K.  CD4+ TRM counts. 
 
YAP and TAZ inhibit CD4+ resident memory and effector memory T cell 
generation during pneumococcus infection. 
 We also tested the effect of T cell specific deletion of YAP and TAZ on 
memory T cell development using a bacterial infection model, pneumococcus 
infection (Streptococcus pneumoniae serotype SP19). WT and Y/T-cKO mice 
were infected intratracheally with pneumococcus and their lungs were harvested 6 
weeks later for T cell phenotyping. Interestingly, in contrast to our observations 
with the influenza infection, we did not observe any changes in activation or 
memory marker expression in Y/T-cKO CD8+ T cells compared to WT (Figure 4.3). 
We did however observe a significant increase in the proportion of CD69+ as well 
as CD44+ CD4+ T cells in the Y/T-cKO compared to the WT (Figure 4.4B, D). A 
higher percentage of Y/T-cKO CD4+ T cells were of the CD4+CD44+CD62L- 
effector memory and CD4+CD44+CD62L-CD69+CD11A+ resident memory 
phenotype compared to WT CD4+ T cells, as well (Figure 4.4E, F). These results 
suggest that TAZ and YAP inhibit CD4+ T cell activation and differentiation to 






Figure 4.3. Lung pneumococcus infection does not affect CD8+ memory T 
cell formation in YAP/TAZ-cKO mice. WT and YAP/TAZ-cKO mice were infected 
with pneumococcus SP19 twice one week apart and 6 weeks later, they mice 
euthanized and their lungs were collected for phenotypic analysis by flow 
cytometry. Statistical differences were determined by using a Student’s t-test. A. 
Percent CD8+ of CD45+. B. Percent CD69+ of CD8+. C. Percent CD62L+ of CD8+.  






Figure 4.4. Increased CD4+ T cell activation and memory formation in 
pneumococcus infected lungs of YAP/TAZ-cKO mice. WT and YAP/TAZ-cKO 
mice were infected with pneumococcus SP19 twice one week apart and 6 weeks 
later, they mice euthanized, and their lungs were collected for phenotypic analysis 
by flow cytometry. Statistical differences were determined by using a Student’s t-
test. A. Percent CD4+ of CD45+. B. Percent CD69+ of CD4+. C. Percent CD62L+ of 
CD4+.  D. Percent CD44+ of CD4+.  E. Percent CD44+CD62L- of CD4+. F. Percent 
TRM of CD4+.  
 
4.4 Conclusions and Future Directions  
 
 In this study, we identify transcriptional regulators YAP and TAZ as 
suppressors of T cell activation, infiltration and effector memory and resident 
memory T cell differentiation. TAZ and YAP deficiency increased the infiltration of 
CD8+CD69+ activated T cells in an influenza infection model and of CD4+CD69+ T 




specific YAP deficiency in cancer, these results suggest that YAP and TAZ inhibit 
T cell activation and infiltration to the site of inflammation [112]. We have also 
previously reported that YAP deficiency results in enhanced sensitivity to micro-
environmental signals as evidenced by increased CD4+ T cell differentiation to 
various effector subsets under respective polarized conditions [112]. These 
findings are supported by the current study, as significant differences in lung 
infiltrating T cell activation and memory T cell differentiation between WT and Y/T-
cKO mice is observed under infection conditions.  
 Future work is necessary to characterize the functional properties of the 
Y/T-cKO memory T cells. Importantly, are the higher numbers of memory T cells 
in the Y/T-cKO mice due to better T cell lung infiltration, altered differentiation or 
differences in proliferation compared to WT? Do Y/T-cKO memory T cells possess 
increased proliferation and/or cytokine secretion capacities? Are they more 
protective against secondary infection? Are they influenza or pneumococcus 
antigen specific? Most importantly, is there a way to induce Y/T inhibition in 
vaccine regimens to improve generation of antigen specific T cell memory? Based 
on transcriptional data from TILs and what is known about the development of 
memory T cells, it is possible that TAZ and YAP affect chromatin architecture and 
accessibility upon T cell activation, as they do in other settings [204]. Interestingly, 
de novo methyltransferase Dnmt3a, deletion of which was found to reduce 
methylation of naïve-associated genes resulting in accelerated memory T cell 




would also be interesting to test the ability of single YAP or TAZ deficiency to affect 
T cell memory. Altogether, our findings support a critical role of TAZ and YAP in 
suppressing CD4+ and CD8+ memory T cell development upon bacterial and viral 
infection and offer new avenues for improvement of vaccine efficacy. 
 
4.5 Materials and Methods 
Mice and infections 
YAP-loxP/loxP; TAZ-loxP/loxP mice provided by Dr. Jeff Wrana and 
previously described [184] were bred with the Tg(Cd4-cre)1Cwi (Jax: 022071) 
[185] and LSL-EYFP (Jax: 006148) [186] lines to derive YAP-loxP/loxP; LSL-
EYFP; CD4-Cre mice. All experiments were performed with 6-10 weeks old mice. 
Animal protocols and study designs were approved by Boston University School 
of Medicine and UMBC. Mice were maintained in pathogen-free facilities at BUMC 
and UMBC and were PCR genotyped using published protocols [184-186]. 
 For influenza infections, 500FFU of influenza virus, strain PR8 were instilled 
intranasally into WT and Y/T-cKO mice. For pneumococcus infections, mice were 
infected with two doses of 1×106 CFU Streptococcus pneumoniae serotype 19F 
one week apart.   
 
Lung digestion  
 Six weeks after infection, mice were anesthetized and intravenously 




were euthanized and their lungs were collected, mechanically disrupted and 
digested in serum free media containing 2mg/ml collagenase type I (Worthington) 
and DNase I (Sigma) for 30 minutes at 37C in a rotator. Lung digests were 
then passed through a 70µm mesh (Falcon) using an insulin syringe plunger and 
washed with PBS. Cells were treated with ACK red blood cell lysis buffer (Gibco) 
and lung single cell suspensions were prepared for staining and analysis by flow 
cytometry. For determining absolute numbers of lung infiltrating T cells by flow 
cytometry, AccuCount fluorescent particles (Spherotech) were added to the lung 
digests. 
 
Flow cytometry  
Lung digests were washed with PBS and stained with the LIVE/DEAD 
fixable near-IR dead cell stain kit (Invitrogen). Cells were then washed with stain 
buffer (BD), resuspended in stain buffer containing Fc block (BD) and incubated 
for 5 minutes at 4C. Surface antibodies were added in predetermined 
concentrations and cells were incubated for 30 minutes at 4C or 15 minutes at 
room temperature, before being washed with BD stain buffer and resuspended in 
PBS for flow cytometric analysis. The following antibodies were purchased from 
BD: CD3 BUV395, CD4 BUV805. The following antibodies were purchased from 
Biolegend: CD8 Alexa700, CD69 BV421, CD44 BV650, CD45 BV510, CD62L 
PECy7, CD11A PE, CD103 BV605. Cells were stained with CD45 BV10 Flow 















Defects in T cell development can lead to serious pathologies, yet the 
molecular mechanisms controlling these processes are poorly understood. Here, 
we report an essential role for Hippo pathway kinases LATS1 and LATS2 
(LATS1/2) in T cell development and homeostasis. We show that CD4-Cre 
recombinase-driven conditional co-deletion of the LATS1/2 genes in mice results 
in defective T cell development that manifests into lymphopenia and animal 
lethality potentially due to lymphopenia induced autoimmunity. LATS1/2 deletion 
leads to excessive thymocyte apoptosis and accumulation of post-positive 
selection, mature single positive thymocytes. These cells downregulate CCR7, 
essential for medullary migration and negative selection of developing thymocytes. 
In blood and secondary lymphoid organs, T cells display an activated, 
effector/memory phenotype. Importantly, adoptive transfer of LATS1/2 deficient 
thymocytes leads to the recipients’ premature death. Collectively, our study reveals 
an essential role for LATS1/2 kinases in lymphocyte development and 
homeostasis and suggest that LATS1/2 inhibition could be involved in pathologies 





5.2 Introduction  
Successful lymphocyte development in the thymus results in the formation 
of mature CD4+ and CD8+ self-tolerant T cells that can recognize foreign antigens 
presented on self MHC [65]. During this highly orchestrated process, developing 
thymocytes are presented with self-peptides at different stages, first to ensure that 
they can recognize self, and second to ensure that they self-tolerant. These 
checkpoints are positive and negative selection. Precursor CD4+CD8+ double 
positive (DP) cells expressing a rearranged T-cell receptor (TCR) localize in the 
thymic cortex and are positively selected for survival and differentiation after 
successfully forming low avidity TCR:self-peptide-MHC interactions. The 
positively selected thymocytes then become CD4+ or CD8+ single positive 
(CD4SP, CD8SP) cells that undergo further maturation. Concurrently with 
positive selection, CD4SP and CD8SP thymocytes upregulate CCR7 which 
enables them to localize in the medulla, where SP cells that strongly interact 
with self-antigens are deleted by negative selection [64]. Therefore, the migratory 
ability of thymocytes to enter these specialized microenvironments is crucial in 
regulating thymocyte maturation [64]. If normal T cell development is disrupted, 
serious health problems arise, such as immunodeficiency, autoimmunity or 
cancer.  
Kinases MST1 and MST2 have been extensively studied in thymocyte 
development, regulatory T cell function, T cell activation and survival as well as 




autoimmunity [131, 133-135, 137-139, 205-209]. Loss of function mutations in 
STK4 (MST1) leads to immunodeficiency with autoimmune manifestations in 
humans, partly through excessive T cell apoptosis, a finding phenocopied in 
MST1 deficient mice [131, 135, 139, 205, 206]. In the thymus, MST1 deletion 
leads to increased proportion of mature SP thymocytes that are unable to 
emigrate from the thymus resulting in lymphopenia, while in the blood and 
secondary lymphoid organs there is an increased proportion of activated effector 
T cells [131, 133, 134, 138]. Defective thymic egress was found to be a result of 
loss of sensitivity to CCR7 ligand chemokines CCL19 and CCL21, while 
migration within the thymus was also abrogated due failure of rho family GTPase 
activation and polarization of the actin cytoskeleton, as well as due to defective 
thymocyte trafficking by LFA-1 and ICAM-1 [131, 133, 134, 138]. This integrin 
interaction is also necessary for self-antigen recognition in the thymus, and loss 
of MST1 led to escape of self-reactive T cells due to inefficient negative selection 
in the thymic medulla, and development of autoimmunity [138]. MST1 and MST2 
deficiency contributes to autoimmunity though impaired Treg development and 
function, in addition to impaired negative selection of SP thymocytes [138, 207-
209]. 
MST1/2 are upstream regulators of the Hippo pathway: once activated, they 
phosphorylate and activate kinases LATS1 and LATS2 (LATS1/2), which in turn 
phosphorylate transcriptional regulators TAZ and YAP, leading to their cytoplasmic 




implicated in regulating inflammation and autoimmunity, but no link has been 
established with thymic T cell development. In line with the roles of the Hippo 
pathway in other organ systems, Hippo pathway activation was shown to link clonal 
expansion with terminal differentiation of activated CD8+ T cells by means of 
contact inhibition through CD80-CTLA4 interactions [130]. TAZ is a RORγt 
activator and necessary for TH17 differentiation and function, while YAP has been 
implicated in Treg differentiation and function [16, 147]. LATS1 protein expression 
is upregulated upon TCR and IL2 stimulation of CD8+ T cells and LATS1/2 
phosphorylation resistant mutant YAP inhibits terminal T cell differentiation [130]. 
However, the effects of MST1 deletion in naïve T cell hyperproliferation and 
defective thymocyte migration and development have been reported to be 
independent of LATS1/2. T cell specific deficiency of NDR1/2 proteins, which 
belong to the same family of kinases as LATS1/2, also leads to lymphopenia and 
mature SP cell accumulation in the thymus due to thymic egress defects [134, 137, 
139]. In humans, patients with acute lymphoblastic leukemia show LATS2 
promoter methylation and decreased expression, which is linked to poor prognosis 
and resistance to chemotherapy [210, 211]. 
Given the broad involvement of the Hippo pathway in T cell development 
and function and the limited reports on the role of LATS1/2 in these processes, we 
aimed to study the two kinases in T cells. For this purpose, we generated T cell 
specific LATS1/2 knockout (LATS1/2-cKO) mice. LATS1/2 deficiency resulted in 




inspection of the thymus revealed elevated thymocyte apoptosis and upregulated 
TCR and CD5 in DP and SP stages of thymocyte development, suggesting 
elevated TCR signaling strength. CD69 was upregulated in the DP stage, but 
downregulated in the SP stages, suggesting augmented SP thymocyte maturation. 
Indeed, the proportion of DP cells in the thymus of cKO mice was decreased, while 
a larger portion of thymocytes were stuck in mature stages of CD4SP and CD8SP 
development. TCR+ LATS1/2-cKO SP cells downregulated CCR7, indicating 
defects in progressing through positive selection. At 16 weeks of age, LATS1/2-
cKO mice presented with lymphopenia, likely due to inability of mature SP 
thymocytes to exit the thymus, while circulating, spleen and lymph node CD4+ and 
CD8+ T cells were of the activated effector/memory phenotype. Adoptive cell 
transfer of LATS1/2-cKO thymocytes to immunodeficient mice led to the hosts’ 
death. The above observations support an essential role for LATS1/2 in thymocyte 
survival, development and homeostasis. 
 
5.3 Results  
Premature death, thymic atrophy and spleen hypertrophy in LATS1/2 c-KO 
mice. 
To study the role of kinases LATS1/2 in T cells, we generated a mouse 
model whereby LATS1/2 deletion and EYFP expression are induced under the 
control of the CD4 promoter (LATS1-loxP/loxP: LATS2-loxP/loxP: LSL-EYFP; 




LATS1/2-cKO mice die at approximately 16 weeks of age (Figure 5.1A) at which 
point they weigh significantly less than their WT littermates (Figure 5.1B). The 
spleens of LATS1/2-cKO mice are hypertrophic (Figure 1C) while their thymuses 
are hypertrophic (Figure 5.1D) compared to WT littermates, suggesting that 
LATS1/2 knockout results in T cell developmental defects. 
 
 
Figure 5.1. LATS1/2-cKO mice die at 16 weeks of age and present with lower 
body and thymus weight, and splenomegaly. Mice were aged and survival was 
monitored over time. At 16 weeks of age, mouse body, thymus and spleen weight 
were measured. Statistical differences were determined by using a Student’s t-
test. A. Survival curve of WT vs LATS1/2-cKO mice (n=9/group). B. Body weight 
of WT vs LATS1/2-cKO mice (WT, n=6; LATS1/2-cKO, n=4). C. Spleen weight of 
WT vs LATS1/2-cKO mice (WT, n=6; LATS1/2-cKO, n=4). D. Thymus weight of 





LATS1/2 regulate thymocyte survival. 
Given previous reports of increased apoptosis in MST1-cKO mice, we 
hypothesized that the observed thymic atrophy could be a result of reduced 
numbers of developing thymocytes due to elevated apoptosis. We confirmed that 
the absolute number of DN, DP, CD8SP and CD4SP thymocytes was significantly 
reduced in the LATS1/2-cKO mice (Figure 5.2A-E). Using an Annexin-7AAD 
assay we show that the percentage of Annexin+7AAD+ late apoptotic DP and SP 
cells increased significantly in the LATS1/2-cKO thymuses (Figure 5.2F-H). These 
results suggest that kinases LATS1/2 are important for thymocyte survival, but they 
could also hint at developmental defects within the thymus, where apoptosis is part 





Figure 5.2. LATS1/2-cKO thymocytes are apoptotic. At 16 weeks of age, 
thymuses were harvested from WT and LATS1/2-cKO mice for phenotypic 
analysis of T cell developmental stages by flow cytometry (DN-double negative, 
DP-double positive, CD4SP-CD4 single positive, CD8SP-CD8 single positive). 
Statistical differences were determined by using a Student’s t-test. A. Dot plots 
representing CD4SP, CD8SP, DP and DN populations in WT vs LATS1/2-cKO 
thymuses. B. Number of cells in the DN stage of T cell development (WT, n=3; 
LATS1/2-cKO, n=5). C. Number of cells in the DP stage of T cell development 
(WT, n=3; LATS1/2-cKO, n=5). D. Number of cells in the CD4 SP stage of T cell 
development (WT, n=3; LATS1/2-cKO, n=5). E. Number of cells in the CD8 SP 
stage of T cell development (WT, n=3; LATS1/2-cKO, n=5). F. Percentage of cells 
in the DN stage of T cell development (WT, n=3; LATS1/2-cKO, n=5). G. 
Percentage of cells in the DP stage of T cell development (WT, n=3; LATS1/2-
cKO, n=5). H. Percentage of cells in the CD4 SP stage of T cell development (WT, 
n=3; LATS1/2-cKO, n=5). I. Percentage of cells in the CD8 SP stage of T cell 
development (WT, n=3; LATS1/2-cKO, n=5) 
 
Accumulation of post-positive selection CD4SP and CD8SP thymocytes in 
LATS1/2-cKO mice. 
Looking into proportions of DN, DP and SP cells in the thymuses of WT vs 
cKO mice, we found that there is a significantly lower proportion of cells in the DP 
stage, while a significantly higher percentage of thymocytes are in the CD4SP and 
CD8SP stages of development (Figure 5.3A-D). To delineate the stage of 
development the thymocytes are in with respect to positive selection in WT vs cKO 
mice, we used markers TCR and CD69, as both are upregulated upon positive 
selection [212]. Pre-selection thymocytes are TCRβloCD69- (stage 1), thymocytes 
directly after TCR engagement are TCRβintCD69int (stage 2), and cells directly after 
undergoing positive selection are TCRβhiCD69hi (stage 3). As thymocytes mature 
post positive selection, they downregulate CD69 and become TCRβhiCD69- (stage 




decrease in the proportion of pre-selection thymocytes in LATS1/2-cKO mice, 
while there is a significant increase in the percentage of mature post-selection 
thymocytes (Figure 5.3E-I). While CD69 marks recently activated T cells, CD5 is 
an indicator of the strength of TCR signaling and can be used in conjunction with 
TCR to mark similar stages of thymocyte development: TCRloCD5lo (stage 1) 
marks preselection DP thymocytes, TCRloCD5int (stage 2) marks DP cells initiating 
positive selection, TCRintCD5hi (stage 3) marks thymocytes in the process of 
positive selection, and TCRhiCD5hi (stage 4) marks post-selection CD4SP and 
CD8SP thymocytes [213, 214]. Using these two markers, we found again that the 
percentage of LATS1/2-cKO thymocytes in the pre-selection stage is significantly 
lower compared to WT, while there is a significant increase in the percentage of 





Figure 5.3. Post-positive selection LATS1/2-cKO thymocytes accumulate in 
the SP stage in the thymus. Thymuses from WT and LATS1/2-cKO mice were 
collected and stained for flow cytometric analysis to determine positive selection 
defects. Statistical differences were determined by using a Student’s t-test. A. 
Percentage of cells in the DN stage of thymocyte development in WT vs LATS1/2-
cKO mice (WT, n=7; LATS1/2-cKO, n=5). B. Percentage of cells in the DP stage 
of thymocyte development in WT vs LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, 
n=5). C. Percentage of cells in the CD4SP stage of thymocyte development in WT 
vs LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, n=5). D. Percentage of cells in 
the CD8SP stage of thymocyte development in WT vs LATS1/2-cKO mice (WT, 
n=7; LATS1/2-cKO, n=5). E. Dot plot of CD69 and TCR expression on WT vs 




LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, n=5). G. Percentage of 
TCRintCD69int thymocytes in in WT vs LATS1/2-cKO mice (WT, n=7; LATS1/2-
cKO, n=5). H. Percentage of TCRhiCD69hi thymocytes in in WT vs LATS1/2-cKO 
mice (WT, n=7; LATS1/2-cKO, n=5). I. Percentage of TCRhiCD69- thymocytes in 
in WT vs LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, n=5). J. Dot plot of CD5 
and TCR expression on WT vs LATS1/2-cKO thymocytes. K. Percentage of 
TCRloCD5lo thymocytes in in WT vs LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, 
n=5). L. Percentage of TCRloCD5int thymocytes in in WT vs LATS1/2-cKO mice 
(WT, n=7; LATS1/2-cKO, n=5). M. Percentage of TCRintCD5hi thymocytes in in WT 
vs LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, n=5). N. Percentage of 
TCRhiCD5hi thymocytes in in WT vs LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, 
n=5). 
 
LATS1/2-cKO CD4SP and CD8SP thymocytes are mature and downregulate 
CCR7. 
Positively selected medullary CD4SP and CD8SP thymocytes 
(TCRβ+CCR7+) can be further functionally defined for their ability to proliferate, 
emigrate and produce cytokines by the expression of CD69 and MHCI: 
CD69+MHCI- are semi-mature (SM) cells, CD69+MHCI+ are mature 1 (M1) and 
CD69-MHCI+ are mature 2 (M2) cells, based on proliferation (M1 and M2), 
emigration (M2) and cytokine production (M2) capacities [148]. We found that 
although LATS1/2-cKO CD4SP and CD8SP thymocytes significantly upregulate 
TCR compared to WT controls (Figure 5.4A-C), a significantly lower percentage 
of them expresses CCR7 (Figure 5.5A, F). For both CD4SP and CD8SP 
thymocytes, the percentage of cells in the SM and M1 stages of SP development 
was significantly lower in the LATS1/2-cKO, while percentage of cells in the most 
mature stage, M2, was significantly higher compared to WT (Figure 5.5B-E, G-




observed in MST1-cKO mice, whereby accumulation of SP cells in the thymus 
is attributed partly to disabled S1P and CCR7 ligand chemokine induced 
chemotaxis [131, 133, 134, 138].  
 
Figure 5.4. SP and DP LATS1/2-cKO thymocytes upregulate TCR and CD5, 
while SP thymocytes downregulate CD69. Thymocytes from WT and LATS1/2-
cKO mice were processed into a single cell suspension and analyzed by flow 




were determined by using a Student’s t-test. A. Percentage of TCR+ DP 
thymocytes in in WT vs LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, n=5). B. 
Percentage of TCR+ CD4SP thymocytes in in WT vs LATS1/2-cKO mice (WT, n=7; 
LATS1/2-cKO, n=5). C. Percentage of TCR+ CD8SP thymocytes in in WT vs 
LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, n=5). D. Percentage of CD5+ DP 
thymocytes in in WT vs LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, n=5). E. 
Percentage of CD5+ CD4SP thymocytes in in WT vs LATS1/2-cKO mice (WT, n=7; 
LATS1/2-cKO, n=5). F. Percentage of CD5+ CD8SP thymocytes in in WT vs 
LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, n=5). G. Percentage of CD69+ DP 
thymocytes in in WT vs LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, n=5).  H. 
Percentage of CD69+ CD4SP thymocytes in in WT vs LATS1/2-cKO mice (WT, 
n=7; LATS1/2-cKO, n=5). I. Percentage of CD69+ CD8SP thymocytes in in WT vs 
LATS1/2-cKO mice (WT, n=7; LATS1/2-cKO, n=5).  
 
 
Figure 5.5. SP LATS1/2-cKO thymocytes downregulate CCR7 and are more 
mature. Thymocytes from WT and LATS1/2-cKO mice were processed into a 
single cell suspension and analyzed by flow cytometry to determine the extent of 
maturation of SP cells. Statistical differences were determined by using a Student’s 
t-test. A. Percentage of CCR7+TCR+ CD4SP thymocytes in in WT vs LATS1/2-
cKO mice (WT, n=3; LATS1/2-cKO, n=5). B. Plot of CD69 and MHC-I expression 




Percentage of semi-mature (SM) WT vs LATS1/2-cKO CD4SP thymocytes (WT, 
n=3; LATS1/2-cKO, n=5). D. Percentage of mature 1 (M1) WT vs LATS1/2-cKO 
CD4SP thymocytes (WT, n=3; LATS1/2-cKO, n=5). E. Percentage of mature 2 
(M2) WT vs LATS1/2-cKO CD4SP thymocytes (WT, n=3; LATS1/2-cKO, n=5). F. 
Percentage of CCR7+TCR+ CD8SP thymocytes in in WT vs LATS1/2-cKO mice 
(WT, n=3; LATS1/2-cKO, n=5). G. Plot of CD69 and MHC-I expression on WT vs 
LATS1/2-cKO CD8SP thymocytes (WT, n=3; LATS1/2-cKO, n=5). H. Percentage 
of semi-mature (SM) WT vs LATS1/2-cKO CD8SP thymocytes (WT, n=3; 
LATS1/2-cKO, n=5). I. Percentage of mature 1 (M1) WT vs LATS1/2-cKO CD8SP 
thymocytes (WT, n=3; LATS1/2-cKO, n=5). J. Percentage of mature 2 (M2) WT vs 
LATS1/2-cKO CD8SP thymocytes (WT, n=3; LATS1/2-cKO, n=5). 
 
Severe reduction in T cell numbers in peripheral blood, spleen and lymph 
nodes of LATS1/2-cKO mice. 
The observation that there is an increased proportion of mature SP 
lymphocytes in the thymuses of KO mice suggests that LATS1/2 kinase activity 
might be necessary for SP lymphocyte egress from the thymus and circulation of 
naïve T cells in the blood, spleen, lymph nodes and other lymphoid organs. If that 
is the case, then we should expect to see fewer CD4+ and CD8+ T cells in lymphoid 
organs. Indeed, there is a dramatic decrease in the number of CD4+ and CD8+ T 
cells in the inguinal lymph nodes, peripheral blood and spleen of LATS1/2-cKO 
mice compared to WT littermates, similar to what is observed in MST1 deficient 
mice (Figure 5.6A-F, H-J) [131, 133-135, 139]. The number of Tregs 
(CD4+Foxp3+CD25+) was also significantly lower in the spleens and peripheral 
blood of LATS1/2-cKO mice (Figure 5.6G, K). These results suggest that thymic 
development perturbances in LATS1/2-cKO mice lead to lymphopenia, potentially 





Figure 5.6. LATS1/2-cKO mice are lymphopenic. Inguinal lymph nodes, spleens 
and peripheral blood were collected from WT and LATS1/2-cKO and subject to 
phenotyping by flow cytometric analysis. Statistical differences were determined 
by using a Student’s t-test. A. Number of CD3+ T cells in the inguinal lymph node 
of WT vs LATS1/2-cKO mice (WT, n=9; LATS1/2-cKO, n=15). B. Number of CD4+ 
T cells in the inguinal lymph node of WT vs LATS1/2-cKO mice (WT, n=9; 
LATS1/2-cKO, n=15). C. Number of CD8+ T cells in the inguinal lymph node of WT 
vs LATS1/2-cKO mice (WT, n=9; LATS1/2-cKO, n=15). D. Number of CD3+ T cells 
per milliliter of peripheral blood of WT vs LATS1/2-cKO mice (WT, n=13; LATS1/2-




LATS1/2-cKO mice (WT, n=13; LATS1/2-cKO, n=17). F. Number of CD8+ T cells 
per milliliter of peripheral blood of WT vs LATS1/2-cKO mice (WT, n=13; LATS1/2-
cKO, n=17). G. Number of regulatory T cells per milliliter of peripheral blood of WT 
vs LATS1/2-cKO mice (WT, n=3; LATS1/2-cKO, n=6). H. Number of CD3+ T cells 
per milligram of spleen of WT vs LATS1/2-cKO mice (WT, n=13; LATS1/2-cKO, 
n=17). I. Number of CD4+ T cells per milligram of spleen of WT vs LATS1/2-cKO 
mice (WT, n=13; LATS1/2-cKO, n=17). J. Number of CD8+ T cells per milligram of 
spleen of WT vs LATS1/2-cKO mice (WT, n=13; LATS1/2-cKO, n=17). K. Number 
of regulatory T cells per milligram of spleen of WT vs LATS1/2-cKO mice (WT, 
n=13; LATS1/2-cKO, n=17). 
 
Increased proportion of activated effector/memory T cells and decreased 
proportion of naïve T cells in the peripheral blood, spleen and lymph nodes 
of LATS1/2-cKO mice. 
 Phenotyping T cells in the peripheral blood, spleen and lymph nodes 
revealed striking changes in the proportions of CD4+ vs CD8+ T cells in WT vs cKO 
mice and in their activation state (Figures 5.7-5.9). In LATS1/2-cKO mice, there is 
a lower percentage of CD4+ T cells and an increased percentage of CD8+ T cells 
(Figure 5.7A-C; Figure 5.8A-C; Figure 5.9A-C). Both CD4+ and CD8+ T cells 
showed increased CD69 expression, suggesting that they are more activated than 
WT (Figure 5.7D, H; Figure 5.8D, H; Figure 5.9D, H). Importantly, there was as 
a significant decrease in the percentage of naïve CD4+ and CD8+ T cells in the 
spleen, peripheral blood and inguinal lymph nodes of LATS1/2-cKO mice 
compared to WT controls, and a significant increase in the percentage of activated 
effector/memory T cells in the KO, as well (Figure 5.7E-G, I-K; Figure 5.8E-G, I-
K; Figure 5.9E-G, I-K). These results, in combination with the fewer numbers of 




result in autoimmunity, also given the strong association between lymphopenia 
and autoimmunity [215], which could be the underlying cause of their premature 
death.  
 
Figure 5.7. T cells in the inguinal lymph nodes of LATS1/2-cKO mice are 
activated and skewed towards an effector/memory phenotype. Inguinal lymph 




flow cytometric analysis. Statistical differences were determined by using a 
Student’s t-test. A. Flow cytometry plot of CD4+ vs CD8+ T cells in WT vs LATS1/2-
cKO mice. B. Percentage of CD4+ T cells in WT vs LATS1/2-cKO mice (WT, n=9; 
LATS1/2-cKO, n=15). C. Percentage of CD8+ T cells in WT vs LATS1/2-cKO mice 
(WT, n=9; LATS1/2-cKO, n=15). D. Percentage of CD4+CD69+ T cells in WT vs 
LATS1/2-cKO mice (WT, n=6; LATS1/2-cKO, n=9). E. Flow cytometry plot of CD44 
and CD62L on CD4+ T cells in WT vs LATS1/2-cKO mice. F. Percentage of CD44-
CD62L+ naïve CD4+ cells in WT vs LATS1/2-cKO mice (WT, n=6; LATS1/2-cKO, 
n=9). G. Percentage of CD44+CD62L- effector/memory CD4+ cells in WT vs 
LATS1/2-cKO mice (WT, n=6; LATS1/2-cKO, n=9). H. Percentage of CD8+CD69+ 
T cells in WT vs LATS1/2-cKO mice (WT, n=6; LATS1/2-cKO, n=9). I. Flow 
cytometry plot of CD44 and CD62L on CD8+ T cells in WT vs LATS1/2-cKO mice. 
J. Percentage of CD44-CD62L+ naïve CD8+ cells in WT vs LATS1/2-cKO mice 
(WT, n=6; LATS1/2-cKO, n=9). K. Percentage of CD44+CD62L- effector/memory 





Figure 5.8. T cells in the peripheral blood of LATS1/2-cKO mice are activated 
and skewed towards an effector/memory phenotype. Peripheral blood was 
collected from WT and LATS1/2-cKO and subject to phenotyping by flow 
cytometric analysis. Statistical differences were determined by using a Student’s 
t-test. A. Flow cytometry plot of CD4+ vs CD8+ T cells in WT vs LATS1/2-cKO mice. 
B. Percentage of CD4+ T cells in WT vs LATS1/2-cKO mice (WT, n=13; LATS1/2-
cKO, n=17). C. Percentage of CD8+ T cells in WT vs LATS1/2-cKO mice (WT, 
n=13; LATS1/2-cKO, n=17). D. Percentage of CD4+CD69+ T cells in WT vs 




CD44 and CD62L on CD4+ T cells in WT vs LATS1/2-cKO mice. F. Percentage of 
CD44-CD62L+ naïve CD4+ cells in WT vs LATS1/2-cKO mice (WT, n=10; LATS1/2-
cKO, n=11). G. Percentage of CD44+CD62L- effector/memory CD4+ cells in WT vs 
LATS1/2-cKO mice (WT, n=10; LATS1/2-cKO, n=11). H. Percentage of 
CD8+CD69+ T cells in WT vs LATS1/2-cKO mice (WT, n=10; LATS1/2-cKO, n=11). 
I. Flow cytometry plot of CD44 and CD62L on CD8+ T cells in WT vs LATS1/2-cKO 
mice. J. Percentage of CD44-CD62L+ naïve CD8+ cells in WT vs LATS1/2-cKO 
mice (WT, n=10; LATS1/2-cKO, n=11). K. Percentage of CD44+CD62L- 






Figure 5.9. T cells in the spleen of LATS1/2-cKO mice are activated and 
skewed towards an effector/memory phenotype. Spleens were collected from 
WT and LATS1/2-cKO and subject to phenotyping by flow cytometric analysis. 
Statistical differences were determined by using a Student’s t-test. A. Flow 
cytometry plot of CD4+ vs CD8+ T cells in WT vs LATS1/2-cKO mice. B. 
Percentage of CD4+ T cells in WT vs LATS1/2-cKO mice (WT, n=13; LATS1/2-
cKO, n=17). C. Percentage of CD8+ T cells in WT vs LATS1/2-cKO mice (WT, 
n=13; LATS1/2-cKO, n=17). D. Percentage of CD4+CD69+ T cells in WT vs 




CD44 and CD62L on CD4+ T cells in WT vs LATS1/2-cKO mice. F. Percentage of 
CD44-CD62L+ naïve CD4+ cells in WT vs LATS1/2-cKO mice (WT, n=10; LATS1/2-
cKO, n=11). G. Percentage of CD44+CD62L- effector/memory CD4+ cells in WT vs 
LATS1/2-cKO mice (WT, n=10; LATS1/2-cKO, n=11). H. Percentage of 
CD8+CD69+ T cells in WT vs LATS1/2-cKO mice (WT, n=10; LATS1/2-cKO, n=11). 
I. Flow cytometry plot of CD44 and CD62L on CD8+ T cells in WT vs LATS1/2-cKO 
mice. J. Percentage of CD44-CD62L+ naïve CD8+ cells in WT vs LATS1/2-cKO 
mice (WT, n=10; LATS1/2-cKO, n=11). K. Percentage of CD44+CD62L- 
effector/memory CD8+ cells in WT vs LATS1/2-cKO mice (WT, n=10; LATS1/2-
cKO, n=11). 
 
To determine whether LATS1/2-cKO lymphocytes derived from the thymus 
have the potential to lead to premature death seen in LATS1/2-cKO mice and rule 
out the possibility of a secondary effect our constitutive Cre-recombinase model, 
we isolated YFP+ lymphocytes from the thymuses of WT and LATS1/2-cKO mice 
and adoptively transferred them to immunocompromised NSG hosts. We found 
that NSG mice receiving LATS1/2-cKO thymus derived lymphocytes weighed 
significantly less that the ones receiving WT cells (Figure 5.10). Importantly, 1/8 
of the KO injected mice died at exactly 16 weeks post adoptive transfer, while 5/8 






Figure 5.10. Adoptive transfer of YFP+ LATS1/2-cKO thymus derived 
lymphocytes to immunocompromised mice results in premature death, 
decreased body weight and increased spleen weight. Lineage traced YFP+ 
thymocytes were sorted from WT or LATS1/2-cKO mice and were adoptively 
transferred to immunocompromised mice. Statistical differences were determined 
by using a Student’s t-test. A. Body weight of immunocompromised mice receiving 
adoptive transfer of YFP+ lymphocytes from WT vs LATS1/2-cKO thymuses. B. 
Spleen weight of immunocompromised mice receiving adoptive transfer of YFP+ 
lymphocytes from WT vs LATS1/2-cKO thymuses. C. Phenotyping of lymphoid 
organs of immunocompromised mice receiving adoptive transfer of YFP+ 
lymphocytes from WT vs LATS1/2-cKO thymuses. D. Immunofluorescence of 
organs of immunocompromised mice receiving adoptive transfer of YFP+ 
lymphocytes from WT vs LATS1/2-cKO thymuses 
 
5.4 Conclusions and Future Directions  
 In this study we have presented evidence for an important role of kinases 
LATS1/2 in thymocyte development and homeostasis. In the absence of LATS1/2, 
thymocytes die excessively of apoptosis resulting in a hypotrophic thymus, while 
single positive cells accumulate in the thymus and make up the majority of 
thymocytes. These single positive cells are able to go through positive selection 
and they are mature, however they do not upregulate CCR7 to WT levels. This 
could lead to SP thymocyte accumulation in the thymus, resulting in loss of T cells 
in the peripheral blood, spleen and lymph nodes of LATS1/2-cKO mice. In addition, 
the existing T cells in the peripheral blood, spleen and lymph nodes are activated 
effector/memory T cells and there is a significant reduction in naïve T cells for both 
CD4+ and CD8+ T cells, as well as regulatory T cells. These observations support 
a scenario where LATS1/2 are necessary for suppression of autoimmunity, as 
LATS1/2-cKO mice die prematurely and present with excessively activated T cells 




 The LATS1/2-cKO phenotype is similar to what is observed in MST1 
deficiency: excessive T cell apoptosis, increased proportion of mature SP 
thymocytes that are unable to emigrate from the thymus resulting in 
lymphopenia, increased proportion of activated effector T cells in the blood and 
secondary lymphoid organs and impaired Treg development and function 
leading to immunodeficiency with autoimmune manifestations [131, 133-135, 
138, 139, 205-209]. Therefore, in contrast to previous reports that MST1 
operates independently of LATS1/2, it is likely that at least part of the MST1 
functions are accomplished through LATS1/2 during thymocyte development. 
Notably, the phenotype is also similar to deficiency of NDR1/2 kinases, which 
together with LATS1/2 comprise the NDR family of kinases [137].  
In the MST1 deficient mice, defective thymic egress was found to be partly 
a result of loss of sensitivity to CCR7 ligand chemokines CCL19 and CCL21, 
which could be the mechanism in place in the case of LATS1/2-cKO mice, as 
well [131, 134, 138]. This possibility is likely given that post-positive selection 
mature CD4SP and CD8SP thymocytes fail to upregulate CCR7 to the same 
extent as WT SP cells. CCR7 is critical in the thymus for SP cell migration from 
the cortex to the medulla [216, 217]. Medullary thymic epithelial cells express 
CCR7 ligands to attract positively selected SP thymocytes that upregulate CCR7 
to a microenvironment where self-reactive thymocytes are deleted by negative 
selection and or adopt a regulatory T cell fate [65, 217-221]. Mice deficient in 




disruptions in establishment of self-tolerance in this way eliciting autoimmune 
diseases [219, 222]. Failure to upregulate CCR7 in the LATS1/2-cKO mice could 
lead to autoimmunity and premature death through perturbed negative selection 
and failure to establish self-tolerance.  
In addition to the possible link between LATS1/2 function and CCR7 
expression, several other questions arise about the involvement of these 
kinases on thymocyte development. One area of future study could be the role 
of LATS1/2 in thymocyte migration. In thymocytes, it is unknown what the 
interactions and regulatory networks are among those two kinases and LFA-1 or 
ICAM-1, rho family GTPases and the actin cytoskeleton, chemokines such as 
CCL19/CCL21 or other signaling molecules like S1P. Classically, LATS1/2 
activity is linked to transcriptional regulators TAZ and YAP, and it would be 
interesting to investigate the involvement of these factors in the LATS1/2-cKO 
phenotype observed in this study. In our study, we used a constitutive Cre 
recombinase mouse model, allowing for LATS1/2 deletion from the DP stages 
of T cell development in the thymus, but it would be interesting to investigate the 
role of LATS1/2 kinases in mature T cell function, potentially with a use of a 
inducible model.  
Collectively, our data reveal an essential role for kinases LATS1/2 in T 
cell development in the thymus. We show that loss of LATS1/2 kinases in the T 
cell compartment leads to immunodeficiency and increased T cell activation that 




autoimmunity. Further studies into the role of LATS1/2 kinases in the regulation 
of lymphocyte development and function can reveal important aspects of 
immune homeostasis and serious pathologies such as immunodeficiency and 
autoimmunity. 
 
5.5 Materials and Methods 
Mouse Strains  
LATS1-loxP/loxP and LATS2-loxP/loxP mice provided by Dr. Randy Johnson and 
previously described [223, 224] were crossed to the the Tg(Cd4-cre)1Cwi (Jax: 
022071) [185] and LSL-EYFP (Jax: 006148) [186] lines to derive LATS1-loxP/loxP; 
LATS2-loxP/loxP; LSL-EYFP; CD4-Cre mice. All experiments were performed with 
14-16 weeks old mice. Animal protocols and study designs were approved by 
Boston University School of Medicine. Mice were maintained in pathogen-free 
facilities at BUMC. 
 
Thymocyte and T cell isolation 
Thymuses, spleens and lymph nodes from WT or LATS1/2-cKO mice were pushed 
through a 70µm mesh (Falcon) using an insulin syringe plunger and washed with 
PBS. Cells were treated with ACK red blood cell lysis buffer and splenocyte single 
cell suspensions were prepared for magnetic separation or stained for sorting by 
flow cytometry. Peripheral blood was collected by cardiac puncture using EDTA 




Flow cytometry  
Single cell suspensions from the thymus, spleen, inguinal lymph nodes or 
peripheral blood were washed with PBS and stained with the LIVE/DEAD fixable 
near-IR dead cell stain kit (Invitrogen). Cells were then washed with stain buffer 
(BD), resuspended in stain buffer containing Fc block (BD) and incubated for 5 
minutes at 4C. Surface antibodies were added in predetermined concentrations 
and cells were incubated for 30 minutes at 4C or 15 minutes at room temperature, 
before being washed with BD stain buffer and resuspended in PBS for flow 
cytometric analysis. The following antibodies were purchased from BD: CD3 
BUV737, CD4 BUV305. The following antibodies were purchased from Biolegend: 
CD8 PerCP-Cy5.5, TCR APC, CD5 PE, CD69 BV421, CD44 BV650, CD62L 
PECy7, CCR7 PECy7, H-2Kb PE, CD25 APC/Fire750, GL3 APC/Fire750, NK1.1 
APC/Fire750, CD45R/B220 APC/Fire750, CD25 BV510. For transcription factor 
staining, the eBioscience Foxp3/ Transcription factor staining buffer set 
(eBioscience) and Foxp3 PE antibody (BD) were used. For absolute counts, 
AccuCount fluorescent particles (Fisher) were added to the sample. Flow 
cytometry analyses were performed on BD LSRII at Boston University School of 
Medicine Flow Cytometry Facility. Flow Cytometry Shared Service and analyzed 





Annexin V/ 7AAD assay 
Following surface staining, thymocytes were washed twice with cold PBS, 
resuspended in 100ul 1× Binding Buffer (BD) and transferred to a FACS tube. 
Annexin V BV421 (BD) and 7-AAD (BD) were added and cells were gently 
vortexed and incubated for 15 min at RT in the dark. After the incubation, 400 µl of 
1× Annexin V Binding Buffer was added to each tube. Samples were analyzed with 
one hour.  
 
Adoptive cell transfers 
For the adoptive cell transfers, EYFP+ WT or LATS1/2-cKO thymocytes 
were stained with LIVE/DEAD fixable near-IR dead cell stain kit (Invitrogen) and 
sorted using a FACSAria. NSG mice (Jax: 005557) [225] were intravenously 






CHAPTER 6: CONCLUSIONS 
 
 This body of work identifies the Hippo pathway as a regulator of cancer 
metabolism and as an important signaling component in T cell development, 
activation and differentiation into effector and memory subsets. In breast cancer, 
we show that YAP/TAZ mediate dependency to exogenous glutamine by 
promoting anaplerosis through direct regulation of the expression of glutamine 
transaminases GOT1 and PSAT1, this way facilitating cancer cell growth and 
survival. In the T cell compartment of the adaptive immune system, we discover 
that YAP is an inhibitor of T cell activation and effector function. YAP is shown to 
inhibit CD4+ T cell polarization into helper subsets and CD8+ T cell infiltration to 
solid tumors. Upon bacterial and viral challenge, YAP/TAZ suppress memory T cell 
generation. Upstream kinases LATS1/2 are revealed to be essential for T cell 
development in the thymus and their deficiency leads to lymphopenia and possibly 
autoimmunity. These results demonstrate the broad involvement of the Hippo 
pathway in cellular processes and reinforce its roles in cell fate regulation in 
development, homeostasis and disease.   
The link between stem cell fate regulation and glutamine metabolism is 
particularly interesting in light of our results in breast cancer. It is likely that 
YAP/TAZ might not only support the bioenergetic demands of breast cancer cells 
for survival and division through glutamine metabolism and anaplerosis, they might 




metastatic abilities. An additional area of interest is the connection between 
contact inhibition and the cytoskeleton with glutamine metabolism. Cell confluency 
reduces transaminase activity as well as YAP/TAZ activity. The latter is achieved 
through cytoskeletal changes affecting YAP/TAZ localization, so it would be 
interesting to investigate how confluency and the cytoskeleton affect glutamine 
metabolism and growth arrest, and how this control is aberrated in cancer. We 
observed that breast cancer cells high in YAP/TAZ are sensitive to transaminase 
blockade, demonstrated by growth inhibition and cell death, whereas cells with low 
YAP/TAZ were not responsive. We propose therefore, that YAP/TAZ expression 
can be used as a biomarker to predict breast cancer cell responsiveness to such 
treatment. 
Our findings describing a novel role of YAP as a suppressor of T cell 
activation and differentiation unveil many areas for further investigation. YAP 
upregulation upon activation acts as a normal regulatory mechanism to suppress 
continued immune activation, just like any checkpoint, and guides T cell 
differentiation. Without YAP, all T cell fates are accessible, even mutually exclusive 
ones (TH1 vs TH2, TH17 vs Treg), and signals from the microenvironment dictate 
which phenotype the T cell is going to adopt. These observations suggest a role 
for YAP in chromatin regulation upon T cell activation. Patterns from out TIL RNA-
Seq analysis emerge in support of this observation: T cell co-activation and co-
inhibition factors are simultaneously upregulated, expression of signature T helper 




genes are induced co-currently, key signaling pathways downstream of the T cell 
receptor are all enriched. It seems as if T cells in the absence of YAP are in a 
combined state of exhaustion and survival, naivety and differentiation. For memory 
T cells, immediate access to both naïve and effector associated genes is what 
establishes their long-term survival, rapid recall capacities and memory status. In 
our infection models, memory T cell generation is significantly augmented in 
YAP/TAZ deficient T cells. It is highly likely therefore that YAP controls T cell fate 
and function through regulating chromatin accessibility.  
Findings from our studies point to the therapeutic potential of YAP inhibition 
in cancer therapy and vaccine development. The findings that YAP deficiency in T 
cells increases CD8+ T cell infiltration and restrains tumor growth provide clear 
prospects for application of YAP inhibition in cancer immunotherapy. Adoptive cell 
transfer of genetically engineered T cells to enhance their antigen recognition, 
survival and activation capacities is promising, however those T cells fail to 
penetrate the immensely immunosuppressive tumor microenvironment. We 
propose that YAP inhibition during T cell expansion and engineering could improve 
the efficacy of adoptive T cell transfer as a cancer therapy. Employing YAP 
inhibition in conjunction with checkpoint inhibition could also improve the success 
rate of checkpoint inhibition therapies, as those fail in non-T cell infiltrated tumors. 
Increased T cell memory generation in response to bacterial and viral infections is 
promising ground for adopting YAP inhibition in vaccine regimes, and it is also a 




augments T cell differentiation in response to the microenvironment provides a 
third avenue for therapeutic exploitation of our findings, as YAP inhibition could be 
used for large scale production of a desirable T cell phenotype (TH1, TH2, TH17, 
Treg). 
The involvement of YAP in T cell biology merits further investigation. How 
does YAP inhibit T cell activation? Is YAP protein located in the cytoplasm or 
nucleus upon TCR and CD28 engagement? What factors is YAP interacting with 
in T cells and how does it suppress expression of genes related to T cell activation, 
differentiation and function? How is YAP expression and function regulated by 
other extracellular and cell surface signaling, for example in response to various 
cytokines or engagement of different co-stimulatory or inhibitory receptors? Does 
YAP control chromatin remodeling and accessibility? How does YAP inhibition lead 
to increased T cell migration and infiltration into tumors or inflamed tissues, like the 
infected lung? How does YAP control T cell memory generation and, importantly, 
does YAP inhibition improve memory T cell responses upon re-infection? Could 
YAP de-regulation be involved in autoimmunity? What about the contribution of 
YAP mediated signaling in T cell development? 
Regarding T cell development, this body of work presents evidence for the 
significance and necessity of LATS1/2 signaling in T cell development and 
maturation in the thymus. In the absence of LATS1/2, mice thymocyte 
development is severely disrupted with mice becoming lymphopenic and 




of de-regulated YAP activation contributing to this phenotype. Given the 
constitutive nature of our mouse models and the fact that T cell specific LATS1/2 
deficiency leads to developmental defects, we did not get the chance to investigate 
the role of kinases LATS1/2 in mature T cell responses. With the use of inducible 
knockout mouse models, it would be interesting to assess LATS1/2 deficiency in 
primary and memory T cell responses and determine how those complement our 
YAP inhibition findings.  
In their totality, the findings presented in this thesis make a strong case for 
the importance of Hippo signaling in regulating cell fate and how deregulated Hippo 
signaling can cause and contribute to pathology. Our results expose novel facets 
of Hippo pathway biology that can be used to develop therapies and understand 
fundamental features of cancer cells and the adaptive immune system. We 
anticipate that further studies on the role of the Hippo pathway in cancer and T cell 
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